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Abstract
To identify genetic variants associated with diabetic retinopathy (DR), we performed a large, 
multiethnic genome-wide association study (GWAS). Discovery included eight European 
cohorts (n = 3,246) and seven African American cohorts (n = 2,611). We meta-analyzed across 
cohorts using inverse-variance weighting, with and without liability threshold modeling of 
glycemic control and duration of diabetes. Variants with a P value < 1 X 10-5 were investigated 
in replication cohorts that included 18,545 Europeans, 16,453 Asians and 2,710 Hispanics.  After 
correction for multiple testing, the C allele of rs142293996 in an intron of nuclear VCP-like 
(NVL) was associated with DR in European discovery cohorts (P = 2.1 x 10-9), but did not reach 
genome-wide significance after meta-analysis with replication cohorts. We applied the Disease 
Association Protein-Protein Link Evaluator (DAPPLE) to our discovery results to test for 
evidence of risk being spread across underlying molecular pathways. One protein-protein 
interaction network built from genes in regions associated with proliferative DR (PDR) was 
found to have significant connectivity (P=0.0009) and corroborated with gene set enrichment 
analyses.  These findings suggest that genetic variation in NVL, as well as variation within a 
protein-protein interaction network that includes genes implicated in inflammation, may 
influence risk for DR.
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Diabetic retinopathy (DR) is a leading cause of blindness.(1) Established risk factors include 
longer duration of diabetes (DoD) and poor glycemic control.(2)  Genetic factors are also 
implicated, with heritability of 52% for proliferative diabetic retinopathy (PDR).(3, 4)  Several 
candidate gene and genome-wide association studies (GWAS) have been conducted.(5-11) 
While several polymorphisms have been suggested to be associated with DR, few have been 
convincingly replicated.(10, 12-15)
There are several reasons why studies have not yielded consistent findings.  The genetic effects 
are likely modest and identification requires large sample sizes. Previous studies have not 
consistently accounted for the strongest two covariates, DoD and glycemic control. Liability 
threshold (LT) modeling is one way to incorporate these covariates while also increasing 
statistical power.(16)  Finally, previous genetic studies have largely examined individual 
variants.  Techniques that examine top GWAS findings collectively for variants that cluster in 
biological networks based on known protein-protein interactions have the potential to identify 
variants where there is insufficient power to detect their individual effects.
The purpose of this study was to identify genetic variants associated with DR by (1) assembling 
a large sample size through inclusion of multiple ethnicities, (2) incorporating DoD and glycemic 
control via LT modeling and (3) collectively examining variants that cluster in biological 
networks.
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Research Design and Methods
All studies conformed to the Declaration of Helsinki tenets and were Health Insurance 
Portability and Accountability Act (HIPAA) compliant. Written informed consent was obtained 
from all participants.  Institutional Review Board /Ethics Committee approval was obtained by 
each individual study. 
Discovery Sample Description
The discovery sample, encompassing seven African American and eight European cohorts, arose 
from a consortium of 11 DR studies for a total of 3246 Europeans and 2611 African Americans. 
(6-8, 12, 13, 17, 18)  Inclusion criteria for the discovery stage were (1) type 2 diabetes and (2) 
European or African American ethnicity. Type 2 diabetes was defined as a fasting plasma 
glucose (FPG)  ≥ 126 mg/dL (7.0 mmol/L) or a hemoglobin A1C (HbA1C) ≥ 6.5% (48 mmol/mol) 
(19) with onset of the diabetes after age 30 years.  Table 1 summarizes the DR phenotyping 
protocols and covariates by discovery cohort. Phenotyping protocols have been previously 
described (4, 20-29) and additional details are in the Supplemental Materials. 
DR Case-Control Definitions
The analysis plan pre-specified four DR case-control definitions with varying Early Treatment 
Diabetic Retinopathy Study (ETDRS) score thresholds for cases and controls (Table 2).(30)  The 
primary case-control definition compared any DR to no DR (ETDRS ≥ 14 vs. ETDRS < 14, 
henceforth referred to as the any DR analysis).  There were three secondary case-control 
definitions.  The first compared patients with PDR to those without PDR (ETDRS ≥ 60 vs. 
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ETDRS < 60, henceforth the PDR analysis).  The second compared those with non-proliferative 
DR (NPDR) or worse to those without DR (ETDRS ≥ 30 vs. ETDRS < 14, henceforth the NPDR 
analysis).  The third compared those with PDR to those without DR (ETDRS ≥ 60 vs. ETDRS < 
14, henceforth the extremes of DR analysis).  The rationale for four definitions is in the 
Supplemental Materials.  Table 1 shows the available samples by cohort and ETDRS score 
thresholds. Supplemental Table 1 summarizes the mean values for glycemic control and DoD.
Statistical Analyses
The genotyping platforms and the numbers of single nucleotide polymorphisms (SNPs) 
genotyped are summarized in Supplemental Table 2. Details about quality control, imputation, 
and data filtering are in the Supplemental Materials. Supplemental Figure 1 provides a flow chart 
of the discovery and replication analyses.  For the four main case-control definition analyses, we 
performed each of the analyses (1) without incorporating DoD and glycemic control using 
EIGENSOFT (16, 31) and (2) with LT modeling of DoD and glycemic control using 
LTSCORE.(16)   LT modeling details are in the Supplemental Materials.  Both the EIGENSOFT 
and LTSCORE tests were implemented in LTSOFT version 2.0 (see Web Resources in 
Supplemental Material). For the discovery analyses, we ran principal components (PC) analysis 
with EIGENSTRAT using only typed SNPs and five PCs, separately by ethnicity and case-
control definition.(32)  We computed association analyses for each of the seven African 
American and eight European cohorts separately and then meta-analyzed by ethnicity. Meta-
analysis was performed using inverse-variance weighting, accounting for both effective sample 
size (defined as 4/[1/Ncase + 1/Ncontrol]) and allele frequency.(33)  We also performed multiethnic 
(Europeans and African Americans together) meta-analyses for the any DR and PDR analyses 
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using inverse-variance weighting and a sensitivity analysis of the any DR meta-analyses in 
African Americans and Europeans (see Supplemental Materials). Because we included rare 
variants in this GWAS, we also tested the robustness of the top associations (P < 5 × 10–8) by 
performing two additional tests: (1) a Fisher’s exact test on cases or controls aggregated across 
all cohorts tested per variant and on each cohort separately and (2) an inverse variance-weighted 
meta-analysis across cohorts using the natural logarithm of the odds ratio as the effect size (34) 
without adjusting for covariates.
P-value thresholds for genome-wide significance
The P-value thresholds for genome-wide significance were based on empirically-determined 
thresholds for different ancestral populations that account for the GWAS multiple testing burden, 
as well as population-specific linkage disequilibrium (LD) patterns (35):
(1) P < 3.24 X 10-8 for SNPs ascertained in African ancestry populations
(2) P < 5.0 X 10-8 for SNPs ascertained in European ancestry populations
(3) P < 3.24 X 10-8 for SNPs ascertained in multiethnic meta-analyses  
We further corrected these thresholds for additional multiple testing from examination of four 
case-control definitions, each with and without covariate incorporation, for eight tests total.  This 
yielded the following P-value thresholds for our study:
(4) P < 3.75 X 10-9 for SNPs ascertained in African ancestry populations 
(5) P < 6.25 X 10-9 for SNPs ascertained in European ancestry populations
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(6) P < 3.75 X 10-9 for SNPs ascertained in multiethnic meta-analyses
We note that correction for eight tests is conservative, because the case-control definitions are 
not completely independent.  We did not apply further multiple testing correction for the 
different ancestries analyzed. 
Replication Meta-Analysis
Eight European, eight Asian and four Hispanic replications cohorts provided summary statistics 
on SNPs with P < 1 X 10-5 in the discovery analyses (Table 3). Their phenotyping/genotyping 
protocols have been previously described and details are in the Supplemental Material. (6-8, 12, 
13, 17, 18)  The rationale for including additional ethnicities in the replication phase is that high 
trans-ethnic genetic correlations have been documented for type 2 diabetes and other 
traits/diseases and support the use of multiethnic studies to increase sample size.(36) 
Supplemental Table 3 summarizes the replication cohorts’ mean values for HbA1C, FPG, and 
DoD. Replication was in silico with existing genotyping. LT modeling was not applied to the 
replication cohort analyses.  The replication cohorts used standard covariate adjustment in their 
regression models. Replication meta-analysis was also performed using inverse-variance 
weighting – first individually by each ethnicity (Europeans, Hispanics, Asians) followed by all 
cohorts combined.  Replicated genome-wide significance had to meet the aforementioned 
thresholds after meta-analysis of the discovery and replication results.  
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Protein-Protein Interaction Analysis of Top GWAS Loci
To identify significantly-enriched protein networks among the loci with the highest statistical 
evidence for association to DR, we applied the Disease Association Protein-Protein Link 
Evaluator (DAPPLE) to our discovery GWAS.(37) It has been shown that top associated loci, 
despite not being genome-wide significant, tend to cluster in biological networks.(37, 38) For 
this reason, we examined the top 1000 loci from the discovery GWAS in the two mono-ethnic 
analyses (European and African American) and for each of the four case-control definitions 
analyses which incorporated DoD and glycemic control (eight network analyses in total). Our 
threshold for significance was therefore P < 0.00625 (0.05 corrected for eight tests). We used the 
publically available version of DAPPLE, and the protocol is outlined in the Supplemental 
Materials. This methodology has been used successfully with previous GWAS to identify protein 
networks with biological relevance.(37-39)
Gene Set Enrichment Analysis of DAPPLE significant genes
To further support the protein-protein interaction results from the DAPPLE analysis, we applied 
gene set enrichment analysis (GSEA) using MAGENTA (Meta-Analysis Gene-Set Enrichment 
of variaNT Associations) (40) to the set of genes significantly enriched for protein-protein 
interactions in the DAPPLE analysis (details in Supplemental Materials).  
Type 2 diabetes and Associated Glycemic Traits Loci
To understand to what extent genetic determination of DR might reflect enrichment for type 2 
diabetes or glycemic control genes, we computed a correlation between case status in the any DR 
analysis and the sum of the beta*risk allele (for quantitative glycemic traits) or logOR*risk allele 
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(for type 2 diabetes) of the trait-associated SNPs for each cohort and each trait (see Supplemental 
Materials for details). 
Results
Discovery Meta-Analysis
Supplemental Figure 2 shows the PC analysis. We observed little inflation in the association 
statistic distribution (Supplemental Figure 3), indicating no significant population stratification 
as a confounder. Supplemental Figure 4 shows the Manhattan plots for the any DR analyses. 
Supplemental Tables 4 - 25 show the top 10 SNPs for independent loci with the lowest P values 
for each discovery analysis, including the sensitivity analyses (full results available at 
https://www.ncbi.nlm.nih.gov/gap).  
Table 4 shows SNPs that met the traditional nominal threshold for genome wide significance of 
P < 5 X 10–8 from the discovery analyses. All of the SNPs in Table 4 were either from the PDR 
or extremes of DR analyses; Figure 1 shows the QQ and Manhattan plots for the PDR and 
extremes of DR analyses. The results for the associations in Table 4 are shown for each cohort 
separately in Supplemental Table 26. Results for these SNPs after meta-analysis with replication 
samples both combined and separated by ethnicity are shown in Table 5 and Supplemental Table 
27, respectively.  
Genome-Wide Significant Finding from the Discovery Analyses in NVL Gene
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Using the corrected significance thresholds, only one SNP in the discovery meta-analyses met 
genome-wide significance: rs142293996 for the extremes of DR analysis incorporating DoD and 
glycemic control in Europeans (P = 2.1 X 10-9). The association was not significant without 
adjusting for covariates based on a Fisher’s exact test (Supplemental Table 28). This is an 
intronic variant in the  nuclear VCP-like (NVL) gene which encodes a member of the AAA 
(ATPases associated with diverse cellular activities) superfamily.(41)  The NVL gene is widely 
expressed in vivo with highest expression in retina 
(https://www.proteinatlas.org/ENSG00000143748- NVL/tissue#top). 
We tested whether this association was a significant cis-expression quantitative trait locus 
(eQTL) in the Genotype-Tissue Expression (GTEx) Project release v7 (see Supplemental 
Materials for eQTL analysis details). This variant, rs142293996, lies in the 22nd intron of NVL 
and is in LD (r2=0.62) with variant rs41271487 in the 24th intron of NVL. Rs41271487 is a 
significant eQTL (P = 6.4 X 10-6, effect size=1.27) in the GTEx spinal cord cervical c-1 tissue, 
targeting calpain 2 (CAPN2), a calcium-activated neutral protease (Supplemental Figure 5). 
Common variants in the intron or regulatory region of CAPN2, 527-576 kb upstream of the DR 
association, are associated with variation in serum alpha-carotene levels (42), a vitamin A 
precursor required for sight, supporting a functional role for this gene. Based on the eQTL 
analysis, increased expression of CAPN2 is associated with decreased risk of DR (Supplemental 
Figure 6).  CAPN2 is expressed in the retina (https://www.proteinatlas.org/ENSG00000162909-
CAPN2/tissue).   
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When examined in the replication analyses (which included a more diverse population), the 
direction of effect in the replication cohorts for rs142293996 was the same but the meta-analysis 
P-value was not genome-wide significant (P = 4.10 X 10-6).  
Top Finding from the African American Discovery Analyses
In African Americans, the SNP with the lowest P value was rs115523882 from the PDR analysis 
(P = 5.37 X 10-9). This was short of the 3.75 x 10-9 threshold for significance in African 
Americans.  We could not reproduce this finding in the replication cohorts. This variant is 
located near the GOLIM4 gene, which helps process proteins and mediates protein transport. The 
SNP rs115523882 specifically changes a motif which is a binding site for Nlx3, a transcription 
factor in blood, suggesting it plays a regulatory role. This variant is mainly present in people of 
African ancestry [minor allele frequency (MAF) = 0.0393] and not common in other ethnic 
groups, suggesting we may have had insufficient power to replicate it.
Of note, there was one SNP, rs184340784, suggestively associated with DR (P = 3.52 X 10-8) in 
the extremes of DR analysis without covariates in African Americans that was not present in our 
replication cohorts (due to low MAF) and thus could not be replicated. Neither rs115523882 nor 
rs184340784 were analyzed for eQTL activity in GTEx due to their low MAF (MAF<0.01 in 
GTEx tissues).
Table 6 and Supplemental Table 29 show the discovery variants with P < 1 X 10-5 that achieved 
a nominal P < 0.05 in the complete replication sample or in one of the replication ethnicities, 
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respectively, and had the same direction as the discovery samples.  None of these variants 
achieved genome-wide significance after discovery and replication meta-analysis, as defined 
above.
DAPPLE Results Protein-Protein Interactions
One protein network from the African American PDR analysis was significant (P=0.0009) for 
average binding degree within the network (Figure 2). The aforementioned top ranked SNP 
(rs115523882) could not be included in the DAPPLE analysis since its nearby gene (GOLIM4) is 
not in the protein database. The significant protein network includes genes with primary roles in 
inflammation including IFNG, IL22RA1, CFH and SELL. INFG encodes INF-γ which is highly 
expressed in ocular tissues from PDR patients.(43) IL22RA1 encodes the IL-22 receptor and 
CFH encodes complement factor H; both proteins are suspected to play a role in PDR.(44, 45) 
SELL encodes L-selectin, which is expressed at higher levels in lymphocytes from DR patients 
and associated with increased endothelial adhesion.(46) We did not identify any statistically 
significant protein networks for any of the other case-control definitions in African Americans or 
in Europeans.
MAGENTA Confirmation of DAPPLE Results
We examined the 41 genes in the significant network identified by the DAPPLE analysis via 
GSEA using MAGENTA.  The genes showed a significant (16.5-fold) enrichment of low 
association P-values in the African American PDR analysis (P < 1 X 10-6; Supplemental Figure 7 
and Supplemental Table 30) and to a lesser extent in African American extremes of DR analysis 
(P =2 X 10-4; Supplemental Table 30), suggesting new DR associations of modest effects in 
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African Americans (Supplemental Table 31). No significant gene set enrichment was found for 
the PDR and extremes of DR analyses in Europeans.
Loci Associated with Type 2 Diabetes and Glycemic Traits
The results of the correlation analysis between type 2 diabetes/glycemic trait-associated SNPs 
and DR case status are shown in Supplemental Table 32.  The Z-score for type 2 diabetes was 
+2.256 (P=0.024).  The correlation coefficient R was positive, indicating that a greater burden of 
SNPs that increase type 2 diabetes risk is correlated with having DR.  However, this Z-score was 
not significant after correcting for the six hypotheses (six traits) tested.  
Previously associated SNPs from Prior Studies
We extracted results from our discovery meta-analysis for the variants with the lowest 
association P-values from previously published DR GWAS or large candidate gene studies 
(Supplemental Table 33).  There were three variants that were nominally significant (P < 0.05) in 
our sample and had the same direction of effect as the previously published studies. Two of the 
variants—rs9896052 and rs6128—were from previous studies whose samples overlapped with 
some samples in our discovery meta-analysis, and therefore do not represent independent 
replication.(10, 20) Variant rs1399634, originally found in Chinese patients (P = 2 x 10-6), was 
nominally significant in our European discovery cohort (P = 0.0124). Meta-analysis of the 
original study and our cohorts was performed using the same method as our discovery and 
replication meta-analyses and was short of genome-wide significance (OR = 1.47, P = 9.63 X 10-
8).
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Discussion
To our knowledge, this study represents the largest GWAS performed for DR. The discovery 
analysis included 3,246 Europeans and 2,611 African Americans. The replication analysis 
included 18,545 Europeans, 16,453 Asians, and 2,710 Hispanics.  Despite the relatively large 
sample size, we did not identify any individual variants that were associated at a genome-wide 
significant level after meta-analysis with multiethnic replication cohorts. However, among the 
most significant results in the African American PDR analysis, we did identify a statistically 
significant enrichment for a network of genes using DAPPLE which was corroborated by GSEA 
using MAGENTA.  
In the discovery meta-analyses, several variants from the PDR and extremes of DR analyses 
achieved nominal genome-wide significance of P < 5 X 10-8, but the only variant to achieve 
genome-wide significance after conservative multiple testing correction was rs142293996 in the 
European analysis for extremes of DR (P = 2.1 X 10-9).  It is notable that the variants with the 
most significant findings came from the two case-control definitions that have PDR as their case 
definition.  This is consistent with the fact that PDR has a higher heritability than overall DR.(4)  
While the most strongly associated variants in the discovery analyses (rs142293996 in NVL in 
Europeans and rs115523882 in GOLIM4 in African Americans) did not reach genome-wide 
significance with replication, it is still possible that they do play a role in DR pathogenesis.  NVL 
is highly expressed in the retina and the implicated variant is in LD with an eQTL acting on 
CAPN2 with functional implications in neural tissue.  The eQTL variant falls in a binding site of 
a transcription factor.(47)   The GOLIM4 variant also has a known regulatory role. 
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We could not replicate the association with rs142293996 when we used the Fisher’s exact test, 
although the Fisher’s exact test did not allow for covariate incorporation.  There is potential for 
inflated false positive rate when standard association methods are applied to rare (e.g. MAF < 
1%) variants in imbalanced (e.g. case fraction < 10%) case-control cohorts at modest sample 
sizes.(48)  However, most cohorts in this study did not have case fraction <10%. Larger sample 
sizes will help determine the confidence in these top associations.
There was one variant suggestively associated in the extremes of DR discovery analysis in 
African Americans, rs184340784, which was not present in any replication datasets.  The T 
allele of this variant has a frequency of 0.0023 in African populations and 0 in European, East 
Asian, South Asian and Hispanic populations in the 1000 Genomes Phase 3 panel.  In the 
discovery analysis, the P = 3.52 X 10-8 was shy of the genome-wide significance threshold of 
3.75 X 10-9 for variants discovered from the African ancestry analyses.  This variant is within an 
intronic region upstream of adherens junctions associated protein 1 (AJAP1) which has its 
highest expression in brain frontal cortex but is also expressed in the retina 
(https://www.proteinatlas.org/ENSG00000196581-AJAP1/tissue).
In the DAPPLE analysis, we did find that the top signals for the PDR analyses in African 
Americans analysis were enriched for a biologic network. The advantage of DAPPLE is that it 
can identify a protein pathway which may not be evident solely from the primary individual 
variant GWAS.  The presence of an underlying network amongst the top loci suggests there are 
likely true associations within top findings that have yet to reach genome-wide significance due 
to limited power.  Multiple pathways including inflammatory pathways are implicated by this 
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network. To confirm biological significance, these results will need to be followed up with 
functional in vitro studies.
The DAPPLE results were corroborated by the MAGENTA GSEA in the African American 
PDR and extremes of DR analyses. This network of genes, however, was not enriched for in 
Europeans. This could either be due to technical differences, e.g., the number of African 
American cases is ~3-fold larger than the number of European cases, or to biological reasons. 
For example, we found that the allele frequencies of the most significant variant per gene for 
40% of these protein interacting genes are rare in Europeans (MAF < 0.2%), while common in 
African Americans (MAF > 1%), according to the Genome Aggregation Database (gnomAD, see 
Web Resources).
In the analysis between type 2 diabetes/glycemic trait SNPs and DR case status, only type 2 
diabetes variants were significantly associated with DR prior to, but not after, multiple testing 
correction.  One previous study examined aggregate effects of 76 type 2 diabetes-associated 
variants in Asian patients.(49) Participants in the top tertile of type 2 diabetes-risk score were 
2.56-fold more likely to have DR compared with lowest tertile participants.  Our study’s result 
showed the same direction of effect as the prior study, with type 2 diabetes risk raising alleles 
increasing DR risk. The prior study did not examine glycemic traits.  Our inability to detect a 
correlation for glycemic traits may be due to the small amount of glycemic variance captured by 
these variants. In European patients, HbA1C SNPs explain approximately 5% of HbA1C 
variance.(50)   
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We were unable to replicate findings from previous studies.(6-8, 12, 13, 17, 18) We did have the 
same direction of effect in our European discovery sample for rs1399634 (LRP2) which was 
initially reported in an Asian population.  However, the meta-analysis was shy of genome-wide 
significance. The overall lack of replication of previous reports’ findings is not surprising, given 
the heterogeneity in phenotyping, case-control definitions, ethnicities and analytic approaches, 
although we did try to match our case-control definitions to the original studies’ definitions.
There are many potential reasons why we were unable to identify replicable, significant 
associations from our discovery GWAS.  First, the genetic risk in DR development may be quite 
small in proportion to the non-genetic risk factors.  Therefore, even though we assembled the 
largest sample, it may not be sufficient to detect very modest effects.  There was heterogeneity 
between the discovery and replication cohorts that could contribute to inability to replicate.  The 
discovery cohort included individuals with type 2 diabetes while the replication cohorts included 
individuals with either type 1 or type 2 diabetes.  It is not known definitively whether genetic 
variants for DR differ between type 1 and type 2 diabetes. Clinically, DR phenotypes are similar 
in patients with type 1 and type 2 diabetes, so we hypothesize that at least some of the genetic 
risk is shared. However, we cannot be certain of this and heterogeneity of diabetes type might 
have contributed to lack of replication. The discovery cohort included individuals who were of 
either European or African American descent while the replication cohorts included individuals 
of European, Hispanic, or Asian descent. This heterogeneity could also have led to lack of 
replication. Europeans were represented in both the discovery and replication phases, but even 
our European discovery analysis has limited power. Power calculations show that our discovery 
GWAS for the any DR analysis in Europeans had 100% power to detect a variant with a MAF of 
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0.40 with a heterozygous genotypic relative risk (GRR) of 1.5 with a P-value < 5 X 10-8, whereas 
the power decreases to 5% for the same variant with GRR of 1.2. 
We attempted to harmonize the phenotypes as much as possible, but there were some limits to 
complete harmonization, particularly for cohorts with limited-field or no photography.  
Misclassification of participants because of limited DR ascertainment could have biased the 
results to the null.  Although we did use LTSCORE modeling to account for DoD, we may have 
had some misclassification bias because we did not have a minimum DoD for controls – i.e. 
some controls could have developed DR with longer DoD - which would also bias our result 
towards the null.  We only had one HbA1c measure. Repeated HbA1c measures would reflect 
long-term glycemia more accurately.  
In summary, we have executed the largest GWAS of DR to date.  There were no genome-wide 
significant findings but analysis of protein-protein interaction networks point to possible 
candidate pathways for PDR in African Americans.  Future studies examining DR genetics 
would benefit from a greater international collaboration encompassing larger samples that would 
allow strict case-control definitions that define a minimal DoD without sacrificing power.  
Furthermore, these studies should focus case definitions on the advanced forms of DR—PDR 
and diabetic macular edema (DME)—and incorporate more refined phenotyping, particularly 
optical coherence tomography for DME. Finally, whole genome sequencing might reveal a role 
for very rare variants, particularly for the DR phenotypic extremes.
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Table 1.  Studies included in the discovery sample
Study Population Diabetes Type
# of Eyes/
# of Fields/
Size of Fields 
Photographed
Diabetes 
Duration
Glycemic 
Control 
Measure
Cases
(ETDRS ≥ 
14)
Ctrls
(ETDRS < 
14)
Cases
(ETDRS ≥ 
60)
Ctrls
(ETDRS < 
60)
Cases
(ETDRS ≥ 
30)
AAPDR AA 2 2/7/30 deg. Y HbA1C 274 56 255 75 261
AGES* EUR 2 2/2/45 deg. Y HbA1C 85 222 3 304 8
ARIC AA 2 1/1/45 deg. Y HbA1C 96 265 3 358 73
EUR 2 1/1/45 deg. Y HbA1C 126 632 6 752 80
AUST EUR 2 NA‡ Y HbA1C 522 435 187 770 346
BMES EUR 2 2/5/30 deg. Y FPG 124 208 1 331 37
CHS AA 2 1/1/45 deg. Y FPG 19 35 4 50 14
EUR 2 1/1/45 deg. Y FPG 26 119 4 141 16
FIND-Eye* AA 2 2/2/45 deg.† Y HbA1C 330 167 264 233 303
EUR 2 2/2/45 deg.† Y HbA1C 158 154 115 197 145
JHS AA 2 2/7/30 deg. Y HbA1C 91 160 12 239 57
MESA AA 2 2/2/45 deg. Y HbA1C 101 258 11 348 60
EUR 2 2/2/45 deg. Y HbA1C 38 200 2 236 12
RISE/RIDE EUR 2 2/7/30 deg. Y HbA1C -- -- 80 117 --
WFU AA 2 NA‡ Y HbA1C -- -- 548 211 --
TOTAL AA 2 -- Y Varies 911 941 1097 1514 768
TOTAL EUR 2 -- Y Varies 1079 1970 398 2848 644
Ctrls= Controls, AAPDR = African American Proliferative Diabetic Retinopathy Study, AGES = Age, Gene/Environment 
Susceptibility Study, ARIC = Atherosclerosis Risk In Communities Study, AUST= Australian Genetics of Diabetic Retinopathy 
Study, BMES = Blue Mountains Eye Study, CHS=Cardiovascular Health Study, FIND-Eye = Family Study of Nephropathy and 
Diabetes-Eye, JHS = Jackson Heart Study, MESA = Multiethnic Study of Atherosclerosis, RIDE/RISE= Ranibizumab Injection in 
Subjects with Clinically Significant Macular Edema with Center Involvement Secondary to Diabetes, WFU=Wake Forest University, 
AA=African American, EUR = European, Illum=Illumina, Affy=Affymetrix, NA=not available, Y=information on diabetes duration 
is available, HbA1C=hemoglobin A1C, FPG=fasting plasma glucose, deg.= degrees, SNPs= single nucleotide polymorphisms, 
QC=quality control
* Cohorts without access to raw genotype information
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† Not all FIND-Eye subjects had photographs but all participants had harmonization of exam and clinical data to an ETDRS score.
‡ The AUST study used examination by an ophthalmologist to ascertain diabetic retinopathy.  The WFU study used a questionnaire to 
ascertain diabetic retinopathy.
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Table 2.  Four case-control definitions and the number of samples available for discovery for each definition.
Controls Cases
Analysis Name Score n AA n EUR Score n AA n EUR
Any DR (Primary Analysis) < 14 941 1970 ≥ 14 911 1079
PDR < 60 1514 2848 ≥ 60 1097 398
NPDR < 14 941 1970 ≥ 30 768 644
Extremes of DR < 14 941 1970 ≥ 60 1097 398
DR= diabetic retinopathy, PDR = proliferative diabetic retinopathy, NPDR = non-proliferative diabetic retinopathy, Score = ETDRS 
score range, AA = African American, EUR= European 
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Table 3. Studies included in the replication meta-analyses
Cohort by Ancestry Ethnicity/
Nationality
DM 
Type
Any DR 
Analysis
PDR Analysis NPDR Analysis Extremes of DR 
Analysis
Cases Controls Cases Controls Cases Controls Case Controls
Asian
KSDR Korean 2 1516 571 918 1167 1300 571 918 571
MESA Chinese 2 28 83 -- -- 17 83 -- --
RIKEN Japanese 2 5532 5565 -- -- 2371 5565 -- --
SCES I Chinese 2 75 228 -- -- -- -- -- --
SCES II Chinese 2 27 78 -- -- -- -- -- --
SiMES Malay 2 214 557 -- -- -- -- -- --
SINDI Indian 2 315 669 -- -- -- -- -- --
TUDR Chinese 2 -- -- -- -- -- -- 436 559
European
DCCT/EDIC 
Primary cohort
North 
American
1 -- -- 53 598 -- -- -- --
DCCT/EDIC
Secondary cohort, 
conventional treatment
North 
American
1 -- -- 114 209 -- -- -- --
DCCT/EDIC
Secondary cohort, intensive 
treatment
North 
American
1 -- -- 42 288 -- -- -- --
GENESIS/GENEDIAB French 1 277 999 808 468 277 607 277 468
GoDARTS Scottish 2506 2412 574 4345 1381 2412 574 2412
GoKinD North 
American
1 -- -- 138 581 -- -- -- --
SUMMIT European 1 and 
2
5422 4302 -- -- -- -- -- --
WESDR North 
American
1 -- -- 309 294 -- -- -- --
Hispanic
GOLDR Hispanics 2 298 301 76 523 215 301 76 301
Page 48 of 100Diabetes
LALES Hispanics 2 552 500 53 999 341 500 53 500
MESA Hispanics 2 92 192 -- -- 52 192 -- --
SCHS Mexican 
Americans
2 528 247 103 672 406 247 103 247
Total 17382 16704 3188 10144 6360 10478 2437 5058
DM = diabetes mellitus, KSDR = Korean Study of Diabetic Retinopathy, MESA = Multiethnic Study of Atherosclerosis, RIKEN  = 
Rikagaku Kenkyusho - Institute of Physical and Chemical Research, SCES= Singapore Chinese Eye Study, SiMES = Singapore 
Malay Eye Study, SINDI = Singapore Indian Eye Study, DCCT/EDIC = Diabetes Control and Complications Trial/Epidemiology of 
Diabetes Interventions and Complications, GENESIS/GENEDIAB=Genetics nephropathy and sib pair study/Genetics, nephropathy, 
diabetes, GoDARTS =Genetics of Diabetes and Audit Research Tayside Study, GoKinD = Genetics of Kidneys in Diabetes, 
SUMMIT = Surrogate markers for Micro- and Macro-vascular hard endpoints for Innovative diabetes Tools, WESDR = Wisconsin 
Epidemiologic Study of Diabetic Retinopathy, GOLDR = Genetics of Latino Diabetic Retinopathy, LALES = Los Angeles Latino Eye 
Study, SCHS = Starr County Health Studies, TUDR = Taiwan–US Diabetic Retinopathy Study
The SUMMIT cohort is a meta-analysis of three European studies: The Finnish Diabetic Nephropathy (FinnDiane) Study; Scania 
Diabetes Registry; and the Eurodiab study.
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Table 4. Variants with P < 5 x 10-8 (traditional, nominal threshold for genome wide significance) in the discovery analyses 
CASES CONTROLS
Case Control 
Definition
Population/
LT Modeling RSID CHR Position Nearest Gene REF N RAF N RAF NEFF P OR 95% CI
PDR AA/no rs115523882 3 167876205 GOLIM4 A 1105 0.9823 1119 0.9611 1452 9.42 X 10-9 3.10 2.12, 4.53
PDR AA/yes rs115523882 3 167876205 GOLIM4 A 1105 0.9823 1119 0.9611 1452 5.37 X 10-9 3.10 2.14, 4.50
PDR EUR/no rs139205645 2 201949806 NDUFB3 T 309 0.9725 975 0.9959 907 3.93 X 10-8 0.13 0.06, 0.27
PDR EUR/yes rs17791488 17 26232732 NOS2/LYRM9 T 309 0.9871 975 0.9661 907 7.26 X 10-9 3.70 2.40, 5.71
Extremes of DR AA/no rs184340784 1 4589883 AJAP1 C 520 0.999 230 0.9784 603 3.52 X 10-8 NA NA
Extremes of DR EUR/yes rs142293996 1 224448059 NVL C 187 0.9947 435 0.9874 523 2.10 X 10-9 2.38 1.80, 3.14
Extremes of DR EUR/yes rs17706958 3 73837141 PDZRN3 T 308 0.8139 594 0.7332 797 3.04 X 10-8 1.58 1.35, 1.85
Extremes of DR EUR/yes rs80117617 2 40855125 SLC8A1 T 308 0.9838 594 0.9445 797 4.04 X 10-8 3.78 2.37, 6.02
LT= liability threshold, RSID= rs identifier, CHR= chromosome, REF= reference allele, NEFF= Effective sample size, RAF= 
reference allele frequency, OR= odds ratio for reference allele, CI = confidence interval, AA= African Americans, EUR = European
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Table 5. Replication results for variants with P < 5 x 10-8 (traditional, nominal threshold for genome wide significance) in the 
discovery analysis 
Discovery 
Population/
LT modeling
RSID Nearest Gene REF DiscNEFF
Disc
RAF Disc P
Disc
OR
All
Rep 
NEFF
All 
Rep
RAF
All
Rep 
OR
All
Rep 
P
Disc + REP OR
(95% CI)
Disc + Rep 
P
Variants identified in the PDR Discovery Analysis
AA/no rs115523882 GOLIM4 A 1452 0.9721 9.42 X 10-9 3.10 571 0.9975 0.20 0.13 2.89 (1.97, 4.23) 8.51 X 10-8
AA/yes rs115523882 GOLIM4 A 1452 0.9721 5.37 X 10-9 3.10 571 0.9975 0.20 0.18 2.89 (1.99, 4.20) 4.25 X 10-8
European/no rs139205645 NDUFB3 T 907 0.9907 3.93 X 10-8 0.13 3431 0.9900 0.74 0.77 0.48 (0.29, 0.79) 0.004
European/yes rs17791488 NOS2/LYRM9 T 907 0.9705 7.26 X 10-9 3.70 5883 0.9772 0.82 0.33 1.08 (0.98, 1.19) 0.12
Variants identified in the Extremes of DR Analysis
AA/no rs184340784 AJAP1 C 603 0.0063 3.52 X 10-8 NA * * * * -- --
European/yes rs142293996 NVL C 523 0.9895 2.10 X 10-9 2.38 1229 0.9910 3.23 0.16 2.91 (1.85, 4.57) 4.10 x 10-6
European/yes rs17706958 PDZRN3 T 797 0.7615 3.04 X 10-8 1.58 4194 0.9828 1.28 0.02 1.39 (1.24, 1.56) 7.41 x 10-8
European/yes rs80117617 SLC8A1 T 797 0.9598 4.04 X 10-8 3.78 3345 0.9726 1.29 0.24 1.71 (1.30, 2.25) 1.35 x 10-4
LT= liability threshold, RSID= rs identifier, CHR= chromosome, REF= reference allele, NEFF= Effective sample size, RAF= 
reference allele frequency in sample, ALL= all replication cohorts, OR= odds ratio for reference allele, CI = confidence interval, PDR 
= proliferative diabetic retinopathy, DR = diabetic retinopathy, AA= African Americans
* None of the replication cohorts were able to provide data for this SNP.
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Table 6. Replication results for variants with nominal significance (P <0.05) in the combined (Hispanic, African American, and 
European cohorts) replication meta-analyses
Discovery Population/
LT modeling RSID Nearest Gene REF*
DISC
EAF
DISC 
OR DISC P
ALL 
REP
OR
ALL 
REP P
DISC + 
REP OR
DISC + 
REP P
Variants identified in the Any DR Discovery Analysis
European (Sens)/no rs1394919 PPEF2/NAAA C 0.72 0.73 8.51 X 10-6 0.91 0.003 0.88 6.35 X 10-6
AA (Sens)/no rs75360147 SLC28A3 T 0.93 2.08 7.07 X 10-6 2.65 0.009 2.17 2.29 X 10-7
European/no rs1508244 HTR1E A 0.98 0.33 3.74 X 10-6 0.92 0.01 0.90 0.002
ME/no rs10432638 UBXN2A C 0.73 0.78 2.60 X 10-6 0.93 0.01 0.89 7.74 X 10-6
EU/no rs150775408 BC031225 C 0.95 1.97 7.24 X 10-6 1.27 0.04 1.46 2.54 X 10-5
AA/yes rs143894698 GCM1 G 0.98 3.14 4.62 X 10-6 1.45 0.004 1.58 2.53 X 10-5
European/yes rs13006587 ATAD2B G 0.58 0.79 7.52 X 10-6 0.93 0.006 0.92 4.74 X 10-5
European/yes rs73642012 PTPRD C 0.91 0.67 9.58 X 10-6 0.90 0.02 0.87 8.67 X 10-5
Variants identified in the PDR Discovery Analysis
Europeans/no rs139921826 PRSS35 G 0.98 0.33 7.92 X 10-6 0.66 0.03 0.62 0.0008
AA/yes rs1414474 C1orf94 C 0.14 1.62 1.46 X 10-7 1.12 0.01 1.19 1.90 X 10-5
AA/yes rs9998354 BTF3P13 T 0.44 0.73 8.74 X 10-6 0.92 0.04 0.87 0.0001
European/yes rs142293996 NVL C 0.99 1.83 1.14 X 10-6 2.40 0.04 2.29 0.0001
Variants identified in the NPDR Discovery Analysis
European/no rs1508244 RN7SL643P A 0.98 0.32 8.13 X 10-6 0.89 0.005 0.87 0.0005
European/no rs7944308 KCNA4 G 0.42 0.71 7.76 X 10-7 0.94 0.02 0.90 5.80 X 10-5
Variants identified in the Extremes of DR Discovery Analysis
AA/no rs74161190 TCERG1L A 0.94 0.32 4.57 X 10-6 0.40 0.03 0.32 7.16 X 10-7
European/yes rs17706958 PDZRN3 T 0.76 1.58 3.04 X 10-8 1.28 0.02 1.39 7.41 X 10-8
European/yes rs10932347 CPS1 A 0.04 0.33 4.22 X 10-7 0.64 0.02 0.55 1.30 X 10-5
AA/yes rs2690028 KAZN C 0.32 0.62 4.52 X 10-6 0.80 0.03 0.74 1.72 X 10-5
European/yes rs116972715 DSC3 C 0.99 2.60 2.48 X 10-6 3.62 0.03 3.29 1.59 X 10-5
European/yes rs75167957 CTNNA2 C 0.99 3.26 3.36 X 10-6 9.77 0.04 6.34 5.83 X 10-6
AA/yes rs6577631 LOC339862 G 0.86 0.53 3.45 X 10-6 0.89 0.04 0.84 0.0006
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Sens= Sensitivity Analysis, ME = Multiethnic, AA = African American, DR = diabetic retinopathy, PDR = proliferative diabetic 
retinopathy, NPDR = non-proliferative diabetic retinopathy. * For insertions-deletion, the reference allele is shown first followed by 
the alternate allele
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Figure Legends
Figure 1. Quantile-quantile and Manhattan plots for the PDR and extremes of DR discovery meta-analyses for: (A and B) PDR 
analysis in African American participants with liability threshold modeling of duration of diabetes and glycemic control; (C and D) 
PDR analysis in European participants with liability threshold modeling of duration of diabetes and glycemic control; (E and F) 
Extremes of DR analysis in African American participants with liability threshold modeling of duration of diabetes and glycemic 
control; and (G and H) Extremes of DR analysis in European participants with liability threshold modeling of duration of diabetes and 
glycemic control. The horizontal line in each of the Manhattan plots indicates the nominal threshold for genome-wide significance (P 
= 5 X 10-8).
Figure 2. Protein network from the African American proliferative diabetic retinopathy discovery analysis that was significant in the 
DAPPLE analysis.  This significant protein network includes genes with primary roles in inflammation (IFNG, IL22RA1, CFH, 
SELL), protein function/endoplasmic reticulum function (ADAMT30, ERP44, HSP90B1, SPON1, CNAX, WFS1), catabolic 
processing/metabolism (PPT1, ALDH1B1), gene expression/transcription factor activity (HNRNPH1, TAF4, POLR2E, TCEB1, 
COMMD1, PLAGL1, THRB, SIN3A), macromolecule transport (NUP153, NUP50), protein localization (SEC61B, SEC61A2), and 
DNA repair/cell cycle (RBBP8, ATM, EEF1E1). 
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Supplemental Materials
Additional Details Regarding Diabetic Retinopathy Phenotyping in the Discovery Cohorts
With the exception of the Wake Forest University (WFU) cohort, all of the discovery cohort samples used photography with Early Treatment 
Diabetic Retinopathy Study (ETDRS) grading for diabetic retinopathy (DR) phenotyping. The WFU cohort based DR diagnosis on questionnaire 
items of previous laser treatment for DR.  Therefore, WFU could only be included in the proliferative DR (PDR) analysis as it was not possible to 
determine the degree of retinopathy in patients without laser treatment to include them in the other analyses.  The Ranibizumab Injection in Subjects 
with Clinically Significant Macular Edema with Center Involvement Secondary to Diabetes (RISE/RIDE) cohort did not include any patients without 
retinopathy and therefore could only be incorporated in the PDR analyses as well.
Rationale for the Four Different Case-Control Definitions
The rationale for using four DR case-control definitions is multiple-fold. First, it allows us to replicate findings from previous studies across a range 
of case-control definitions.  Similarly, it also allows us the greatest opportunity for well-powered replication of our discovery analysis findings since 
the available cohorts for replication use different case-control definitions. The any DR and PDR analyses have the advantages of incorporating the 
largest sample sizes, thus maximizing power.  They also help distinguish if there are genetic variants that increase risk at the earliest stage of 
retinopathy development (any DR) vs. advanced retinopathy (PDR).  To specifically address the genetic basis for the response to retinal ischemia, 
which is responsible for the transition from NPDR to PDR, we performed a post hoc sensitivity analysis of the PDR analysis where we excluded 
participants with no DR and compared participants with NPDR to those with PDR.  The non-proliferative DR (NPDR) analysis addresses whether 
there are genetic variants that influence DR at its intermediate stage.  Because many of the discovery cohorts were population-based studies, they did 
not have large numbers of patients with advanced DR. Thus, the NPDR analysis preserves sample size to some degree while trying to examine a 
more rigorous case-control definition than the any DR analysis.  The extremes of DR analysis was performed with the expectation that the decrease 
in power from smaller sample size would be compensated by enrichment for genetic variants of strong effects in participants at the extremes of DR 
development.
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3Initial Quality Control and Data Filtering
The following data filtering and quality-control measures were employed. First, for each study (e.g. WFU) separately, we removed any SNP with 
minor allele frequency (MAF) <0.1% and with >1% missing data, and that did not have a human genome build 37 physical position and rs id.  Next, 
for each cohort separately, we inferred the continental (EUR, ASI, AFR) ancestry proportions of each individual using SNPweights.(Chen et al., 
2013)  European individuals were defined based on >90% European ancestry.  African American individuals were defined based on >50% African 
ancestry and <10% East Asian ancestry.  We observed that there existed some individuals with African ancestry between 10% and 50% and less than 
10% East Asian ancestry, and these were removed for the primary analyses.  
From this point forward, all data filtering and quality control steps continued to be performed for each study separately and, in addition, were 
performed separately for African Americans and Europeans if that study had both African Americans and Europeans.  A Hardy-Weinberg filter was 
applied for each SNP.  We compared the actual number of heterozygotes to the expected number of heterozygotes based on MAF.  We removed the 
SNP if the actual number of heterozygotes was greater than 5 standard deviations from expected.  
We removed one of each pair of duplicate samples.  Two of the studies recruited patients from overlapping geographic areas and there was a higher 
chance for duplicate samples between them.  The Jackson Heart Study (JHS) overlapped in recruitment area with the Atherosclerosis Risk in 
Communities (ARIC) Study.  For these studies, we merged the cohorts prior to the duplicate check, performed the duplicate check on the reduced set 
of merged SNPs, removed the duplicate sample, and then restored the full set of cohort-specific SNPs to each cohort before proceeding with the 
analyses below.  
1000 Genomes Imputation
Next, imputation was done with the 2.3.0 version of impute2. We used the cosmopolitan reference sample based on 1,092 1000 Genomes Phase 1, 
version 3 samples.  After imputation, any SNP with low imputation accuracy (INFO <0.6), MAF<1%, or < 5 copies in imputed data was removed 
from that cohort.  SNPs that were retained in only a subset of cohorts were included in the meta-analysis.  Association analysis was run on rounded 
dosages, retaining highly uncertain genotypes (e.g. P(most likely genotype)<0.9) so long as the SNP has imputation quality score ≥ 0.6.
Related individuals
After imputation, we removed one of each pair of related individuals separately for each cohort, except for JHS and ARIC where overlap was 
expected as described above. We removed one of each pair of individuals with genome-wide relatedness >0.10 with the smartrel program in 
EIGENSOFT (see Web Resources). This genome-wide relatedness coefficient is analogous to the kinship coefficient.
The quality control steps and analyses were performed for all studies at the Harvard School of Public Health except for the Family Investigation of 
Nephropathy and Diabetes (FIND) and Age/Gene Susceptibility Study (AGES).  For these two studies, the consents and permissions did not allow 
for sharing of individual-level data so these cohorts performed the above analyses at the primary study site and shared their data for meta-analysis.  
Because there was also overlap between WFU and FIND with regards to recruitment area, the FIND study identified cross-study duplicate 
individuals and those were removed from the WFU study for the analyses.
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5using cohorts that ascertained/enrolled diabetic participants without regard to DR status.  For African Americans, these cohorts were JHS, ARIC, 
Cardiovascular Health Study (CHS) and Multi-Ethnic Study of Atherosclerosis (MESA).  For Europeans, these cohorts were ARIC, CHS, MESA, 
and Blue Mountains Eye Study (BMES). The numbers of African American participants who contributed information on DoD, FPG and HbA1c to 
calculate liability-scale effect sizes were 702, 988 and 866, respectively.  The numbers of European participants who contributed information on 
DoD, FPG and HbA1c to calculate liability-scale effect sizes were 917, 1389 and 1013, respectively.
Duration of actual type 2 diabetes is difficult to precisely ascertain in the absence of longitudinal measurement of HbA1C up to disease onset.  For this 
reason, all of our analyses instead use duration of diagnosed type 2 diabetes as a covariate.  Because all covariate effect size estimates are based on 
duration of diagnosed type 2 diabetes and not on duration of actual type 2 diabetes, there is no mismatch between estimated and true effects of 
duration of diagnosed type 2 diabetes.  We acknowledge that the gain in power attained by including the duration of diagnosed type 2 diabetes 
covariate may be lower than the gain in power that can be attained by including the duration of actual type 2 diabetes covariate (with correspondingly 
higher covariate effect size), however the latter analysis is not possible based on available data.  We further note that using a less than maximally 
informative covariate would not introduce false positives, since the purpose of including this covariate is to increase statistical power (DR cases with 
lower duration of diagnosed type 2 diabetes harbor stronger genetic signals) and not to avoid confounding.  
Sensitivity Analyses and Meta-analysis Minimum Sample Sizes
We performed sensitivity analyses of the meta-analysis for the primary any DR analysis by removing cohorts that did not have bilateral grading for 
DR (ARIC, CHS) or did not have fundus photograph grading for retinopathy (FIND).  The rationale for this sensitivity analysis was to limit the 
discovery sample to cohorts with high quality documentation of DR status and thus decrease misclassification that might bias results to the null.
Meta-analysis statistics were computed only for SNPs with at least half of the total available effective sample size.  For any given analysis, only studies 
with at least 10 cases and at least 10 controls (for a given ethnicity) were included. Such low numbers of cases or controls may lead to unstable statistical 
findings.
Replication Cohorts
The replication cohorts chose the index SNP if it was available in their dataset.  The replication cohorts chose the case-control definition from our 
discovery analyses that most closely matched their existing case-control definitions.  If possible, the replication cohorts re-coded their case-control 
definitions to match all of the case-control definitions in the discovery analyses.  However, this was not always feasible and therefore, every cohort 
did not provide information on every case-control definition.  The replication cohorts incorporated DoD and glycemic control using traditional 
adjustment in logistic regression. 
Protein-Protein Interaction Analysis of Top GWAS Loci (DAPPLE) Protocol
We applied the Disease Association Protein-Protein Link Evaluator (DAPPLE) to our discovery GWAS to identify significantly-enriched protein 
networks among the loci with the highest statistical evidence for association to DR.  Each locus was defined based on linkage disequilibrium (r2 > 0.5 
from the associated SNP, then expand to the nearest recombination hotspot). Genes were identified by whether their transcription start or 
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7and 661 individuals, respectively), to identify LD-proxy variants at r2>0.5 [a cutoff shown to capture a substantial proportion of colocalizing eQTL-
GWAS signals(Ongen et al., 2017)], using Plink 1.9 (see Web Resources). If no significant eQTL was found, we checked whether the variants and 
genes in the GWAS locus were tested for eQTL analysis in any of the 48 tissues in GTEx.
Colocalization analysis of eQTL and GWAS associations
For the significant rs41271487-CAPN2 brain spinal cord eQTL found to be in LD (r2=0.62) with the rs142293996 DR association, we assessed the 
probability that the co-occurring GWAS and eQTL signals are tagging the same causal variant, using two Bayesian-based colocalization analysis 
methods: eCAVIAR (Hormozdiari et al., 2016), which assumes allelic heterogeneity in a locus (using the default of 2 causal variants per locus), and 
the coloc.abf function (Giambartolomei et al., 2014), which assumes only one causal variant per locus. For both methods, we used the extremes of 
DR GWAS summary statistics. We followed recommended guidelines for each method. For eCAVIAR, we considered 100 variants upstream and 
downstream of the lead GWAS variant that were tested in both the GWAS and eQTL studies (179 variants total), and used as input z-scores from 
both studies. For the coloc analysis, we analyzed all variant-gene pairs tested for eQTL analysis in GTEx, within 1Mb of the transcript start site of 
CAPN2, which were also tested in the DR GWAS (4,611 variants total). The variant p-values, study-specific MAF, sample sizes, and the GWAS 
case/control ratio were inputted into the analysis. For prior probabilities that a variant is associated with gene expression or disease status we used: 
p1=p2=10-4, and for the probability that the variant is associated with both traits we used: p12=10-6. We used both methods’ recommended significance 
cutoffs: colocalization posterior probability (CLPP)>0.01 for eCAVIAR, and posterior probability for the same variant affecting both traits (PP4) > 
0.9 for coloc.abf. We found no statistical support for the co-occurring DR association, rs142293996, and the rs41271487-CAPN2 spinal cord eQTL 
tagging the same causal variant [eCAVIAR colocalization posterior probability (CLPP) < 0.0056; coloc posterior probability (PP4)=0.002]. 
However, given that the CLPP of the lead GWAS variant, rs142293996, was substantially larger than the CLPP of the surrounding variants (average 
CLPP of other variants=1.5x10-5), the lack of colocalization may be due to the GWAS and eQTL studies being under-powered (NeQTL= 83 and 
Neffective of GWAS=797).
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9Supplemental Table 1.  Clinical Covariate Information by Study and Ancestry for Discovery Cohorts
Cohort Ancestry Cases (ETDRS ≥ 14) Controls (ETDRS < 14)
DoD, 
months
HbA1C
%(mmol/mol)
FPG
mg/dL(mmol/L)
DoD, 
months
HbA1C
%(mmol/mol)
FPG 
mg/dL(mmol/L)
AAPDR AA 249.3 8.47 (69) NA 188.8 7.55 (59) NA
AGES European 176.9 6.78 (51) 150.5 (8.35) 119.7 6.32 (46) 135.9 (7.54)
ARIC AA 147.1 9.65 (82) 244.2 (13.55) 80.1 7.36 (57) 183.1 (10.16)
European 164.5 8.84 (73) 202.8 (11.26) 103.5 6.71 (50) 164.9 (9.15)
AUST European 217.9 8.41 (68) NA 151.5 7.45 (58) NA
BMES European 109.7 NA 173.0 (9.60) 90.27 NA 139.6 (7.75)
CHS AA 168.7 NA 145.2 (8.06) 108.7 NA 184.2 (10.22)
European 191.5 NA 164.4 (9.12) 114.5 NA 140.6 (7.80)
FIND-Eye AA 279.4 7.44 (58) NA 230.5 6.84 (51) NA
European 269.9 7.20 (55) NA 189.4 6.85 (51) NA
JHS AA 180.6 8.45 (69) 162.4 (9.01) 87.9 6.66 (49) 123.5 (6.85)
MESA AA 81.8 7.64 (60) 146.3 (8.12) 59.7 6.99 (53) 134.4 (7.46)
European 14.9 6.91 (52) 140.1 (7.78) 30.1 6.61 (49) 130.7 (7.25)
RISE/RIDE AA 228.7 8.45 (69) 150.0 (8.32) -- -- --
European 194.1 7.60 (60) 152.1 (8.44) -- -- --
WFU AA 294.5 7.63 (60) 150.0 (8.32) -- -- --
AAPDR = African American Proliferative Diabetic Retinopathy Study, AGES = Age, Gene/Environment Susceptibility Study, ARIC = 
Atherosclerosis Risk In Communities Study, AUST= Australian Genetics of Diabetic Retinopathy Study, BMES = Blue Mountains Eye Study, 
CHS=Cardiovascular Health Study, FIND-Eye = Family Study of Nephropathy and Diabetes-Eye, JHS = Jackson Heart Study, MESA = Multi-
Ethnic Study of Atherosclerosis, RIDE/RISE= Ranibizumab Injection in Subjects with Clinically Significant Macular Edema with Center 
Involvement Secondary to Diabetes, WFU=Wake Forest University, AA=African American, NA=not available, DoD=Duration of Diabetes, 
HbA1C=hemoglobin A1C, FPG=fasting plasma glucose
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Supplemental Table 2.  Discovery Study Cohort Details
Study Population Genotyping Platform SNPs genotyped SNPs after QC SNPs after imputation
AAPDR AA Affy 6.0 883851 579834 12194970
AGES* EUR Illum 370 353202 304677 7811063
ARIC AA Affy 6.0 603146 505092 12308412
EUR Affy 6.0 603146 505092 6665985
AUST EUR Illum OmniExpress 605258 603947 6933006
BMES EUR Illum 670 544799 525303 6886208
CHS AA Illum Omni Quad 886457 844504 8501510
EUR Illum 370 886457 844504 2168325
FIND-Eye* AA Affy 6.0 837,210 798920 19463075
EUR Affy 6.0 727,731 690150 8813873
JHS AA Affy 6.0 633267 580336 12441123
MESA AA Affy 6.0 735518 671745 12733230
EUR Affy 6.0 735518 671745 6727876
RISE/RIDE EUR Illum 2.5M 2379855 § §
WFU AA Affy 6.0 868155 817755 7044061
AAPDR = African American Proliferative Diabetic Retinopathy Study, AGES = Age, Gene/Environment Susceptibility Study, ARIC = 
Atherosclerosis Risk In Communities Study, AUST= Australian Genetics of Diabetic Retinopathy Study, BMES = Blue Mountains Eye Study, 
CHS=Cardiovascular Health Study, FIND-Eye = Family Study of Nephropathy and Diabetes-Eye, JHS = Jackson Heart Study, MESA = Multi-
Ethnic Study of Atherosclerosis, RIDE/RISE= Ranibizumab Injection in Subjects with Clinically Significant Macular Edema with Center 
Involvement Secondary to Diabetes, WFU=Wake Forest University, AA = African American, EUR =  European, HbA1C=hemoglobin A1C, 
FPG=fasting plasma glucose
§ The RISE and RIDE studies were imputed separately, RISE has 1174886 SNPs after QC and 7417483 SNPs after imputation.  RIDE had 1607163 
SNPs after QC and 7888767 SNPs after imputation. 
* Cohorts without access to raw genotype information
Page 67 of 100 Diabetes
11
Supplemental Table 3. Clinical Covariate Information by Study and Ancestry for Replication Cohorts
Cohort Cases Controls
Case Definition
DoD, 
months
HbA1C
%(mmol/mol)
FPG
mg/dL(mmol/L) Control Definition
DoD, 
months
HbA1C
%(mmol/mol)
FPG 
mg/dL(mmol/L)
Asian
KSDR Any DR 202 7.9 (63) NA No DR NA 6.8 (51) NA
MESA-Chinese Any DR NA 7.5 (58) 154 (8.6) No DR NA 7.1 (54) 136 (7.6)
RIKEN – Stage 1 Any DR 143 NA NA No DR 159 NA NA
RIKEN- Stage 2 Any DR 165 NA NA No DR 142 NA NA
SCES I/ SCES II/ SiMES/ SINDI Any DR 148 8.3 (67) 202 (11.2) No DR 65 7.5 (58) 168 (9.0)
TUDR PDR 156 8.9 (74) NA No DR 168 9 (75) NA
European
DCCT/EDIC – primary Severe DR 233 9.9 (85) NA No severe DR 216 8 (6.4) NA
DCCT/EDIC – secondary, 
conventional Severe DR 313 9.1 (76) NA No severe DR 294 8.2 (66) NA
DCCT/EDIC – secondary, intensive Severe DR 316 8.7 (72) NA No severe DR 306 7.5 (58) NA
GENESIS/GENEDIAB DR 190 7.8 (62) NA No DR 315 8.5 (69) NA
GoDARTS no or mild DR 286 8.1 (65) NA severe NPDR/PDR 169 7.3 (56) NA
GoKIND laser 385 7.5 (58) NA no laser 290 7.5 (58) NA
SUMMIT – FinnDiane severe DR 379 8.7 (72) NA no/mild DR 340 8.2 (66) NA
SUMMIT- SDR* DKD 388 7.9 (63) NA no DKD 378 7.1 (54) NA
SUMMIT – EuroDiab* DKD 284 8.3 (67) NA no DKD 300 7.7 (61) NA
WESDR No PDR or DME 425 9.3 (78) NA PDR +/- DME 397 8.5 (69) NA
Hispanic
GOLDR Any DR 86 8.9 (74) NA no DR 162 7.8 (62) NA
LALES Any DR 150 8.8 (73) NA no DR 82 8.1 (65) NA
MESA - Hispanics NA NA 8.3 (67) 169 (9.4) NA NA 7.2 (55) 148 (8.2)
SCHS severe NPDR/PDR 217 12.3 (111) 202 (11.2) no or early NPDR 144 10.9 (96) 186 (10.3)
DoD=Duration of Diabetes, HbA1C=hemoglobin A1C, FPG=fasting plasma glucose, NA=not available, DR= diabetic retinopathy, NPDR = non-proliferative diabetic retinopathy, PDR = proliferative diabetic retinopathy, DKD = 
diabetic kidney disease, KSDR = Korean Study of Diabetic Retinopathy, MESA = Multiethnic Study of Atherosclerosis, RIKEN  = Rikagaku Kenkyusho - Institute of Physical and Chemical Research, SCES= Singapore Chinese Eye 
Study, SiMES = Singapore Malay Eye Study, SINDI = Singapore Indian Eye Study, TUDR = Taiwan–US Diabetic Retinopathy Study, DCCT/EDIC = Diabetes Control and Complications Trial/Epidemiology of Diabetes 
Interventions and Complications, GENESIS/GENEDIAB=Genetics nephropathy and sib pair study/Genetics, nephropathy, diabetes, GoDARTS =Genetics of Diabetes and Audit Research Tayside Study, GoKinD = Genetics of 
Kidneys in Diabetes, SUMMIT = Surrogate markers for Micro- and Macro-vascular hard endpoints for Innovative diabetes Tools, FinnDiane = Finnish Diabetic Nephropathy Study, SDR = Scania Diabetes Registry, WESDR = 
Wisconsin Epidemiologic Study of Diabetic Retinopathy, GOLDR = Genetics of Latino Diabetic Retinopathy, LALES = Los Angeles Latino Eye Study, SCHS = Starr County Health Studies
* For these two studies we were unable to obtain a breakdown of the duration of diabetes and glycemic control indicators by diabetic retinopathy status so we present the breakdown by diabetic nephropathy status.
Page 68 of 100Diabetes
12
Supplemental Table 4. Ten independent variants with the lowest P values any DR analysis, African American participants, without accounting for duration of 
diabetes and glycemic control
CASES CONTROLS
RSID CHR POSITION REF* NEFF N REF FREQ N
REF 
FREQ OR P VALUE
rs2104455 6 9368518 A 1495 911 0.8105 948 0.7464 1.57 1.18 X 10-7
rs11771617 7 125373426 A 1445 892 0.9715 913 0.9421 3.12 1.35 X 10-6
rs115489684 5 142116464 C 1495 911 0.8845 948 0.9295 0.57 1.51 X 10-6
rs184033309 5 103622556 T 1445 892 0.9583 913 0.9841 0.33 1.55 X 10-6
rs4901258 14 52696282 G 1495 911 0.5716 948 0.49 1.44 1.91 X 10-6
rs115634195 10 25735812 G 969 517 0.9734 599 0.9934 0.16 1.92 X 10-6
rs7139352 12 61345749 G 1495 911 0.7007 948 0.6342 1.46 2.01 X 10-6
rs202189921 2 236562108 CAAAAATAAATAAAA/C 1445 892 0.9875 913 0.9717 3.73 2.40 X 10-6
rs12095420 1 226788952 C 932 705 0.9965 488 0.9806 7.04 2.58 X 10-6
rs1559674 15 62106284 T 1495 911 0.2852 948 0.342 0.71 3.03 X 10-6
* For insertions/deletions, the first allele listed is the reference allele and the second allele listed is the non-reference allele. DR= Diabetic retinopathy, RSID= rs 
identifier, CHR= chromosome, REF= reference allele, NEFF= Effective sample size, N = sample size, REF FREQ = reference allele frequency, OR = odds ratio
Supplemental Table 5.  Ten independent variants with the lowest P values for any DR analysis, African American participants, with liability threshold modeling of 
duration of diabetes and glycemic control
CASES CONTROLS
RSID CHR POSITION REF NEFF N REF FREQ N REF FREQ OR P VALUE
rs12095420 1 226788952 C 932 705 0.9965 488 0.9806 7.04 9.37 X 10-8
rs74152685 1 247811291 G 978 522 0.9564 592 0.9814 0.39 2.66 X 10-7
rs2300993 5 109038629 G 1495 911 0.9519 948 0.9232 1.83 4.51 X 10-7
rs11771617 7 125373426 A 1445 892 0.9715 913 0.9421 3.12 1.19 X 10-6
rs114790220 8 5163956 T 1445 892 0.9658 913 0.9863 0.34 1.26 X 10-6
rs11662496 18 41275397 A 1495 911 0.495 948 0.5679 0.72 1.38 X 10-6
rs2104455 6 9368518 A 1495 911 0.8105 948 0.7464 1.57 1.54 X 10-6
rs9882204 3 167566283 G 1495 911 0.5373 948 0.4807 1.32 1.83 X 10-6
rs190634129 4 143341715 T 969 517 0.9857 599 0.9933 0.29 1.99 X 10-6
rs73194819 2 13252874 T 1495 911 0.8586 948 0.8884 0.65 2.21 X 10-6
DR= Diabetic retinopathy, RSID= rs identifier, CHR= chromosome, REF= reference allele, NEFF= Effective sample size, N = sample size, REF FREQ = 
reference allele frequency, OR = odds ratio
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Supplemental Table 6.  Ten independent variants with the lowest P values for any DR, European participants, without accounting for duration of diabetes and 
glycemic control
CASES CONTROLS
RSID CHR POSITION REF* NEFF N REF FREQ N
REF 
FREQ OR P VALUE
rs66598691 2 51060137 G 2464 1088 0.9431 1975 0.9053 1.87 3.49 X 10-6
rs1508244 6 87133646 A 1520 774 0.9626 816 0.9877 0.33 3.74 X 10-6
rs55921628 15 47814176 C 2464 1088 0.8802 1975 0.9124 0.66 3.83 X 10-6
rs76557325 5 76299200 A 2464 1088 0.8893 1975 0.9271 0.65 4.02 X 10-6
rs62489286 7 1365867507 C 2464 1088 0.7943 1975 0.8413 0.71 5.78 X 10-6
rs200366339 3 12298312 TTG/T 2218 1003 0.6269 1753 0.6831 0.75 7.09 X 10-6
rs150775408 3 82302346 C 2044 962 0.9652 1343 0.9326 1.97 7.24 X 10-6
rs3113743 4 181471147 C 2464 1088 0.5859 1975 0.5314 1.28 7.27 X 10-6
rs201856528 15 82286425 AAAG/A 1798 877 0.9556 1121 0.9777 0.43 7.43 X 10-6
rs12653353 5 145780135 A 2464 1088 0.2015 1975 0.2486 0.74 9.57 X 10-6
* For insertions/deletions, the first allele listed is the reference allele and the second allele listed is the non-reference allele. DR= Diabetic retinopathy, RSID= rs 
identifier, CHR= chromosome, REF= reference allele, NEFF= Effective sample size,  N = sample size, REF FREQ =  reference allele frequency, OR = odds ratio
Supplemental Table 7.  Ten independent variants with the lowest P values for any DR analysis, European participants, with liability threshold modeling of duration 
of diabetes and glycemic control
CASES CONTROLS
RSID CHR POSITION REF* NEFF N REF FREQ N REF FREQ OR P VALUE
rs142293996 1 224448059 C 1259 646 0.9938 643 0.986 2.2 2.30 X 10-7
rs9905843 17 74869651 C 2464 1088 0.5831 1975 0.6306 0.8 8.74 X 10-7
rs2699116 7 9216486 A 2464 1088 0.9174 1975 0.8876 1.5 9.76 X 10-7
rs8130730 21 45243204 C 2464 1088 0.8040 1975 0.8395 0.8 1.09 X 10-6
rs140675300 8 137699220 C 2044 962 0.9621 1343 0.9348 1.7 1.48 X 10-6
rs7241056 18 3381626 A 2464 1088 0.2553 1975 0.2266 1.2 1.91 X 10-6
rs151166811 9 110284659 C/CAAAAT 1798 877 0.9709 1121 0.9501 1.8 3.52 X 10-6
rs200071549 16 70563931 G/GGAGGCTGA 1670 839 0.1212 921 0.0852 1.5 4.29 X 10-6
rs117958555 19 41628014 G 1387 684 0.8004 843 0.7562 1.3 4.53 X 10-6
rs2727270 11 61603237 C 2044 962 0.9029 1343 0.8690 1.4 4.56 X 10-6
* For insertions/deletions, the first allele listed is the reference allele and the second allele listed is the non-reference allele. DR= Diabetic retinopathy, RSID= rs 
identifier, CHR= chromosome, REF= reference allele, NEFF= Effective sample size,  N = sample size, REF FREQ =  reference allele frequency, OR = odds ratio
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Supplemental Table 8.  Ten independent variants with the lowest P values for PDR Analysis, African American participants, without accounting for duration of 
diabetes and glycemic control
CASES CONTROLS
RSID CHR POSITION REF NEFF N REF FREQ N
REF 
FREQ OR P VALUE
rs115523882 3 167876205 A 1452 1105 0.9823 1119 0.9611 3.1 9.42 X 10-9
rs137949823 5 43743109 G 1452 1105 0.9072 1119 0.941 0.43 6.15 X 10-8
rs7533141 1 217716877 T 1452 1105 0.6213 1119 0.5509 1.47 2.85 X 10-7
rs78340493 4 43638196 C 1452 1105 0.8579 1119 0.8186 1.66 3.01 X 10-7
rs1144964 12 69338637 G 1452 1105 0.3674 1119 0.4254 0.67 4.08 X 10-7
rs149201869 2 216352519 T 1364 1082 0.9945 532 0.9765 5.57 8.62 X 10-7
rs73228199 3 111316364 G 1452 1105 0.9254 1119 0.9522 0.36 1.13 X 10-6
rs184340784 1 4589883 C 754 534 0.999 321 0.9829 Undefined 1.15 X 10-6
rs73347124 10 54680020 A 1452 1105 0.9688 1119 0.9857 0.2 1.54 X 10-6
rs2037601 2 196282058 T 1452 1105 0.3294 1119 0.2806 1.44 1.57 X 10-6
PDR= Proliferative diabetic retinopathy, RSID= rs identifier, CHR= chromosome, REF= reference allele, NEFF= Effective sample size, N = sample size, REF 
FREQ = reference allele frequency, OR = odds ratio
Supplemental Table 9.  Ten independent variants with the lowest P values for PDR Analysis, African American participants, with liability threshold modeling of 
duration of diabetes and glycemic control
CASES CONTROLS
RSID CHR POSITION REF NEFF N REF FREQ N REF FREQ OR P VALUE
rs115523882 3 167876205 A 1452 1105 0.9823 1119 0.9611 3.1 5.37 X 10-9
rs1414474 1 34663411 C 1452 1105 0.8792 1119 0.8324 1.6 1.46 X 10-7
rs71354195 19 36876318 G 1452 1105 0.9814 1119 0.962 2.3 3.72 X 10-7
rs73050171 3 174519478 G 1452 1105 0.8561 1119 0.8061 1.5 4.79 X 10-7
rs11201335 10 86778199 C 1452 1105 0.586 1119 0.55 1.3 8.49 X 10-7
rs11488711 1 229241233 C 1452 1105 0.7751 1119 0.8074 0.7 1.00 X 10-6
rs138683663 18 56862782 C 1174 838 0.9952 805 0.9832 4.9 1.03 X 10-6
rs75348186 10 37071613 T 1452 1105 0.9665 1119 0.9423 1.9 1.26 X 10-6
rs7604016 2 62192135 A 1406 1093 0.0238 880 0.0438 0.4 1.41 X 10-6
rs7139429 12 116118551 A 1452 1105 0.8606 1119 0.8311 1.5 1.69 X 10-6
PDR= Proliferative diabetic retinopathy, RSID= rs identifier, CHR= chromosome, REF= reference allele, NEFF= Effective sample size,  N = sample size, REF 
FREQ =  reference allele frequency, OR = odds ratio
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Supplemental Table 10.  Ten independent variants with the lowest P values for the PDR Analysis, European participants, without accounting for duration of 
diabetes and glycemic control
CASES CONTROLS
RSID CHR POSITION REF* NEFF N REF FREQ N REF FREQ OR P VALUE
rs139205645 2 201949806 T 907 309 0.9725 975 0.9959 0.13 3.93 X 10-8
rs202105116 17 15899617 C/CA 907 309 0.9482 975 0.9851 0.26 1.71 X 10-7
rs202159532 11 96159584 A/AT 601 187 0.9626 770 0.9942 0.15 4.24 X 10-7
rs1087427 5 99705657 G 1097 389 0.8278 1092 0.7399 1.69 6.86 X 10-7
rs141785043 2 105038245 C 1097 389 0.7481 1092 0.8242 0.61 8.88 X 10-7
rs141145674 1 187073283 T 907 309 0.966 975 0.9923 0.22 9.82 X 10-7
rs115487191 11 125879341 T 907 309 0.9693 975 0.9934 0.23 1.74 X 10-6
rs35174795 10 87399545 G 1018 356 0.9241 1043 0.9669 0.41 1.80 X 10-6
rs7833313 8 121236971 A 1097 389 0.4229 1092 0.3324 1.51 1.87 X 10-6
rs118027686 21 29806610 T 601 187 0.9545 770 0.989 0.23 2.76 X 10-6
* For insertions/deletions, the first allele listed is the reference allele and the second allele listed is the non-reference allele. PDR= Proliferative diabetic 
retinopathy, RSID= rs identifier, CHR= chromosome, REF= reference allele, NEFF= Effective sample size, N = sample size, REF FREQ = reference allele 
frequency, OR = odds ratio
Supplemental Table 11.  Ten independent variants with the lowest P values for the PDR Analysis, European participants, with liability threshold modeling of 
duration of diabetes and glycemic control
CASES CONTROLS
RSID CHR POSITION REF NEFF N REF FREQ N REF FREQ OR P VALUE
rs17791488 17 26232732 T 907 309 0.9871 975 0.9661 3.7 7.26 X 10-9
rs6038419 20 6294054 A 1097 389 0.9177 1092 0.8686 1.8 1.09 X 10-7
rs17256891 3 55104767 A 907 309 0.9984 975 0.9852 3.6 2.17 X 10-7
rs62413933 6 53330900 C 1097 389 0.982 1092 0.9579 2.9 2.28 X 10-7
rs77017556 5 97479293 T 1018 356 0.9888 1043 0.9727 2.8 3.26 X 10-7
rs142293996 1 224448059 C 601 187 0.9947 770 0.9903 1.8 1.14 X 10-6
rs115630068 3 34231058 T 907 309 0.9871 975 0.9671 2.8 1.54 X 10-6
rs1087427 5 99705657 G 1097 389 0.8278 1092 0.7399 1.7 2.11 X 10-6
rs140790006 1 177641541 T 1097 389 0.5154 1092 0.4350 1.4 2.45 X 10-6
rs828579 9 22166971 A 1097 389 0.6157 1092 0.5659 1.3 2.48 X 10-6
PDR= Proliferative diabetic retinopathy, RSID= rs identifier, CHR= chromosome, REF= reference allele, NEFF= Effective sample size, N = sample size, REF 
FREQ = reference allele frequency, OR = odds ratio
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Supplemental Table 12.  Ten independent variants with the lowest P values for the NPDR Analysis, African American participants without accounting for duration 
of diabetes and glycemic control
CASES CONTROLS
RSID CHR POSITION REF NEFF N REF FREQ N REF FREQ OR P VALUE
rs148995025 5 7085207 A 1218 754 0.9884 913 0.9689 3.41 6.39 X 10-7
rs61741249 7 157309591 C 1029 695 0.9642 683 0.9854 0.16 1.08 X 10-6
rs1360935 13 55143426 T 865 436 0.9788 697 0.9971 0.27 1.64 X 10-6
rs115885880 10 105720104 A 865 436 0.9853 697 0.9971 0.10 1.95 X 10-6
rs10878791 12 68609046 G 1258 768 0.5444 948 0.6104 0.67 1.96 X 10-6
rs150557761 7 63671293 C 1258 768 0.9000 948 0.9442 0.48 3.00 X 10-6
rs7332766 13 106007555 A 1258 768 0.6218 948 0.6974 0.67 3.42 X 10-6
rs6763376 3 167604119 G 1258 768 0.1737 948 0.1332 1.57 3.51 X 10-6
rs145279814 1 72796513 A 1218 754 0.9648 913 0.9416 2.78 3.84 X 10-6
rs78141810 18 35931012 C 1218 754 0.9442 913 0.9710 0.44 4.12 X 10-6
NPDR= non-proliferative diabetic retinopathy, RSID= rs identifier, CHR= chromosome, REF= reference allele, NEFF= Effective sample size, N = sample size, 
REF FREQ = reference allele frequency, OR = odds ratio
Supplemental Table 13.  Ten independent variants with the lowest P values for the NPDR Analysis, African American participants, with liability threshold 
modeling of duration of diabetes and glycemic control
CASES CONTROLS
RSID CHR POSITION REF* NEFF N REF FREQ N REF FREQ OR P VALUE
rs202069793 9 107475294 TGA/T 1339 768 0.3651 948 0.3010 1.39 6.29 X 10-8
rs184340784 1 4589883 C 707 NA NA NA NA Undefined 5.62 X 10-7
rs12656571 5 109078040 G 1339 768 0.948 948 0.9227 1.89 8.01 X 10-7
rs142610219 8 116918264 A 919 433 0.9967 599 0.9850 Undefined 9.62 X 10-7
rs200295620 3 167890185 AT/A 1299 754 0.9889 913 0.9732 2.42 1.36 X 10-6
rs74816310 5 73266734 G 1299 754 0.9863 913 0.9688 Undefined 1.95 X 10-6
rs74966374 5 55905540 C 1299 754 0.9792 913 0.9705 2.13 2.19 X 10-6
rs145764941 5 67857981 C 1299 754 0.9573 913 0.9399 1.63 2.34 X 10-6
rs201685870 5 98692371 TTA/T 1339 768 0.1665 948 0.2068 0.69 2.36 X 10-6
rs201581084 1 158733766 G/GAAATA 1339 768 0.7511 948 0.6878 1.44 2.48 X 10-6
* For insertions/deletions, the first allele listed is the reference allele and the second allele listed is the non-reference allele. NPDR= non-proliferative diabetic 
retinopathy, RSID= rs identifier, CHR= chromosome, REF= reference allele, NEFF= Effective sample size, N = sample size, REF FREQ = reference allele 
frequency, OR = odds ratio, NA = not available
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Supplemental Table 14.  Ten independent variants with the lowest P values for the NPDR analysis, European participants without accounting for duration of 
diabetes and glycemic control
CASES CONTROLS
RSID CHR POSITION REF* NEFF N REF FREQ N REF FREQ OR P VALUE
rs200063790 20 2229666 C/CT 1593 643 0.9597 1753 0.9886 Undefined 1.62 X 10-7
rs426500 5 122467316 T 1711 677 0.326 1975 0.2552 1.45 5.08 X 10-7
rs17702306 20 896753 T 1081 498 0.9830 594 0.9478 3.18 5.30 X 10-7
rs7944308 11 30054459 G 1711 677 0.3644 1975 0.4347 0.70 7.76 X 10-7
rs143467814 15 65765671 A 1309 563 0.9610 1121 0.9844 Undefined 9.99 X 10-7
rs1316491 1 245999838 T 1711 677 0.6372 1975 0.7040 0.71 1.81 X 10-6
rs1829255 15 24315588 G 1711 677 0.6069 1975 0.5466 1.33 2.34 X 10-6
rs12199358 6 158655375 A 1711 677 0.5936 1975 0.6585 0.71 4.20 X 10-6
rs76512108 11 5613131 G 1381 585 0.7713 1143 0.7021 1.49 4.36 X 10-6
rs4634045 3 74108823 T 1711 677 0.7728 1975 0.8225 0.70 6.70 X 10-6
* For insertions/deletions, the first allele listed is the reference allele and the second allele listed is the non-reference allele. NPDR= non-proliferative diabetic 
retinopathy, RSID= rs identifier, CHR= chromosome, REF= reference allele, NEFF= Effective sample size, N = sample size, FREQ = frequency, OR = odds ratio
Supplemental Table 15.  Ten independent variants with the lowest P values for the NPDR Analysis, European participants, with liability threshold modeling of 
duration of diabetes and glycemic control
CASES CONTROLS
RSID CHR POSITION REF* NEFF N REF FREQ N REF FREQ OR P VALUE
rs80117617 2 40855125 T 1122 510 0.9794 794 0.9490 Undefined 7.80 X 10-8
rs142293996 1 224448059 C 896 383 0.9935 643 0.9860 Undefined 1.03 X 10-7
rs181278228 19 10414126 C 888 380 0.9961 657 0.9856 Undefined 8.87 X 10-7
rs117958555 19 41628014 G 941 395 0.8089 843 0.7562 1.35 1.15 X 10-6
rs117241684 16 78093913 C 1247 547 0.9954 1002 0.9821 Undefined 1.66 X 10-6
rs17017690 3 316189 T 1706 677 0.9122 1975 0.8774 1.57 2.43 X 10-6
rs200183045 17 16247098 G/GC 941 395 0.9848 843 0.9751 Undefined 3.12 X 10-6
rs79120131 17 73886532 G 1014 417 0.9940 865 0.9809 Undefined 3.13 X 10-6
rs80187193 10 20038077 A 1133 514 0.9903 713 0.9740 2.35 3.64 X 10-6
rs148819275 2 171987611 ATATATC/A 1588 643 0.9038 1753 0.9304 0.67 4.08 X 10-6
* For insertions/deletions, the first allele listed is the reference allele and the second allele listed is the non-reference allele. NPDR= non-proliferative diabetic 
retinopathy, RSID= rs identifier, CHR= chromosome, REF= reference allele, NEFF= Effective sample size,  N = sample size, REF FREQ =  reference allele 
frequency, OR = odds ratio
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Supplemental Table 16.  Ten independent variants with the lowest P values for the Extremes of DR Analysis, African American participants, without accounting 
for duration of diabetes and glycemic control
CASES CONTROLS
RSID CHR POSITION REF NEFF N REF FREQ N REF FREQ OR P VALUE
rs184340784 1 4589883 C 603 520 0.9990 230 0.9784 Undefined 3.52 X 10-8
rs4726066 7 151322272 G 690 543 0.9864 648 0.9616 Undefined 5.02 X 10-8
rs78464534 2 115991851 C 690 543 0.9836 648 0.9524 Undefined 2.64 X 10-7
rs61811867 1 154775244 C 690 543 0.9731 648 0.9385 Undefined 1.19 X 10-6
rs2064196 6 144587183 C 690 543 0.2493 648 0.3276 0.55 1.22 X 10-6
rs12447665 16 5537598 C 690 543 0.786 648 0.7271 1.83 1.65 X 10-6
rs11575234 12 56744276 C 690 543 0.4168 648 0.5038 0.57 1.97 X 10-6
rs1566115 6 99632323 G 690 543 0.3349 648 0.2632 1.87 2.12 X 10-6
rs9446832 6 73783508 T 690 543 0.9829 648 0.967 Undefined 2.28 X 10-6
rs4129798 3 18280998 A 690 543 0.7332 648 0.7991 0.55 2.47 X 10-6
DR= Diabetic retinopathy, RSID= rs identifier, CHR= chromosome, REF= reference allele, NEFF= Effective sample size,  N = number of subjects, REF FREQ =  
reference allele frequency, OR = odds ratio
Supplemental Table 17.  Ten independent variants with the lowest P values for the Extremes of DR Analysis, African American participants, with liability 
threshold modeling of duration of diabetes and glycemic control
CASES CONTROLS
RSID CHR POSITION REF* NEFF N REF FREQ N REF FREQ OR P VALUE
rs200295620 3 167890185 AT/A 690 543 0.9927 648 0.9715 1.39 7.06 X 10-8
rs184340784 1 4589883 C 603 520 0.999 230 0.9784 Undefined 2.97 X 10-7
rs114921230 1 226782862 G 646 531 0.9963 488 0.9806 1.90 5.37 X 10-7
rs1000708 12 60083488 C 690 543 0.2048 648 0.2706 Undefined 6.91 X 10-7
rs71354195 19 36876318 G 690 543 0.982 648 0.96 2.42 8.00 X 10-7
rs116396065 8 122129270 T 690 543 0.7778 648 0.7246 Undefined 1.16 X 10-6
rs78464534 2 115991851 C 690 543 0.9836 648 0.9524 2.14 1.33 X 10-6
rs201584991 8 125991724 CATT/C 690 543 0.8901 648 0.8485 1.63 1.47 X 10-6
rs74705672 8 133054627 A 648 532 0.987 390 0.9643 0.69 1.47 X 10-6
rs200197449 14 101156145 CTTTCTTTCTT/C 506 288 0.7446 592 0.7969 1.44 1.51 X 10-6
* For insertions/deletions, the first allele listed is the reference allele and the second allele listed is the non-reference allele. DR= Diabetic retinopathy, RSID= rs 
identifier, CHR= chromosome, REF= reference allele, NEFF= Effective sample size, N = number of subjects, REF FREQ =  reference allele frequency, OR = odds 
ratio
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Supplemental Table 18.  Ten independent variants with the lowest P values for the Extremes of DR Analysis, European participants without accounting for 
duration of diabetes and glycemic control
CASES CONTROLS
RSID CHR POSITION REF* NEFF N REF FREQ N REF FREQ OR P VALUE
rs140543605 7 76951640 G 797 594 0.9612 308 0.9941 0.15 8.74 X 10-7
rs76319596 18 74086357 G 797 594 0.9466 308 0.9857 0.20 9.43 X 10-7
rs9765 1 169101526 A 523 435 0.9733 187 1 Undefined 9.77 X 10-7
rs202105116 17 15899617 C/CA 797 594 0.9482 308 0.9857 0.26 1.25 X 10-6
rs58196296 3 74196589 C 797 594 0.8884 308 0.9503 0.40 1.77 X 10-6
rs2993334 13 113570995 C 797 594 0.7944 308 0.6902 1.72 4.00 X 10-6
rs2509462 18 2681138 T 797 594 0.0324 308 0.0051 6.52 4.23 X 10-6
rs147971778 1 159274231 A/AT 797 594 0.9627 308 0.9916 0.22 5.22 X 10-6
rs200035846 3 137896135 A/ATG 797 594 0.7298 308 0.8232 0.57 5.44 X 10-6
rs12326669 18 24065283 G 797 594 0.8398 308 0.7458 1.82 5.56 X 10-6
* For insertions/deletions, the first allele listed is the reference allele and the second allele listed is the non-reference allele. DR= Diabetic retinopathy, RSID= rs 
identifier, CHR= chromosome, REF= reference allele, NEFF= Effective sample size, N = number of subjects, REF FREQ = reference allele frequency, OR = odds 
ratio
Supplemental Table 19.  Ten independent variants with the lowest P values for the Extremes of DR Analysis, European participants with liability threshold 
modeling of duration of diabetes and glycemic control
CASES CONTROLS
RSID CHR POSITION REF* NEFF N REF FREQ N REF FREQ OR P VALUE
rs142293996 1 224448059 C 523 187 0.9947 435 0.9874 2.38 2.10 X 10-9
rs17706958 3 73837141 T 797 308 0.8139 594 0.7332 1.58 3.04 X 10-8
rs80117617 2 40855125 T 797 308 0.9838 594 0.9445 3.77 4.04 X 10-8
rs181278228 19 10414126 C 523 187 0.9973 435 0.9874 4.77 2.14 X 10-7
rs17256891 3 55104767 A 797 308 0.9984 594 0.9882 3.1 2.28 X 10-7
rs188425511 14 23749992 A 523 187 0.984 435 0.9678 2.04 2.90 X 10-7
rs202105116 17 15899617 C/CA 797 308 0.9482 594 0.9857 0.26 3.44 X 10-7
rs10932347 2 211533070 A 797 308 0.0178 594 0.0455 0.33 4.22 X 10-7
rs201817087 14 67070639 CAA/C 523 187 1 435 0.9885 Undefined 4.32 X 10-7
rs12174773 6 4695787 C 797 308 0.3236 594 0.4276 0.63 9.63 X 10-7
* For insertions/deletions, the first allele listed is the reference allele and the second allele listed is the non-reference allele. DR= Diabetic retinopathy, RSID= rs 
identifier, CHR= chromosome, REF= reference allele, NEFF= Effective sample size,  N = number of subjects, FREQ =  frequency, OR = odds ratio
Page 76 of 100Diabetes
20
Supplemental Table 20.  Ten independent variants with the lowest P values for the any DR Analysis, Multiethnic Analysis, without accounting for covariates
RSID CHR POSITION REF* NEFF MAF OR P VALUE
rs202087767 10 128244090 AAAG/A 3714 0.2361 1.31 3.25 X 10-7
rs60678552 6 116610201 C 3960 0.1303 1.41 1.31 X 10-6
rs17058810 18 73784174 C 3960 0.0367 1.84 2.29 X 10-6
rs5996194 22 42986513 T 3960 0.1662 0.73 2.50 X 10-6
rs10432638 2 24202512 C 3960 0.2652 0.78 2.60 X 10-6
rs12550405 8 39470136 T 3960 0.4288 0.80 2.74 X 10-6
rs10058442 5 7481314 C 3190 0.098 1.53 2.83 X 10-6
rs779139 5 116260113 G 3960 0.497 0.81 3.34 X 10-6
rs201856528 15 82286425 AAAG/A 2254 0.0254 0.42 3.54 X 10-6
rs118030504 12 60837470 C 2500 0.037 0.51 4.13 X 10-6
* For insertions/deletions, the first allele listed is the reference allele and the second allele listed is the non-reference allele. DR= Diabetic retinopathy, RSID= rs 
identifier, CHR= chromosome, REF= reference allele, NEFF= Effective sample size, MAF = minor allele frequency, OR = odds ratio
Supplemental Table 21.  Ten independent variants with the lowest P values for the PDR Analysis, Multiethnic Analysis, without accounting for covariates
RSID CHR POSITION REF* NEFF MAF OR P VALUE
rs115523882 3 167876205 A 1452 0.0279 3.10 9.42 X 10-9
rs1601780 13 83557758 G 2550 0.19 0.66 1.95 X 10-7
rs78340493 4 43638196 C 1452 0.1629 1.65 3.01 X 10-7
rs149201869 2 216352519 T 1364 0.0113 5.57 8.62 X 10-7
rs141785043 2 105038245 C 2461 0.1509 0.70 1.08 X 10-6
rs7792156 7 152855875 T 2550 0.375 1.37 1.45 X 10-6
rs73347124 10 54680020 A 1452 0.0226 0.20 1.54 X 10-6
rs200035846 3 137896135 A/ATG 2272 0.124 0.65 1.73 X 10-6
rs35836657 19 12768948 T 1541 0.0828 0.56 1.86 X 10-6
rs116521242 12 68595896 G 1452 0.0528 0.43 2.12 X 10-6
* For insertions/deletions, the first allele listed is the reference allele and the second allele listed is the non-reference allele. PDR= Proliferative diabetic 
retinopathy, RSID= rs identifier, CHR= chromosome, REF= reference allele, NEFF= Effective sample size, MAF = minor allele frequency, OR = odds ratio
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Supplemental Table 22.  Ten independent variants with the lowest P values for the any DR, African Americans, Sensitivity Analysis, without accounting for 
covariates
RSID CHR POSITION REF NEFF MAF OR P VALUE
rs115330915 5 106563985 G 1164 0.0348 0.32 5.95 X 10-8
rs4726066 7 151322272 G 1164 0.0247 3.33 1.30 X 10-7
rs184340784 1 4589883 C 641 0.0063 16.42 1.59 X 10-7
rs140572960 2 134144064 T 1164 0.0284 0.28 7.11 X 10-7
rs2104455 6 9368518 A 1164 0.226 1.58 1.67 X 10-6
rs1006396 22 30017000 G 1164 0.0485 2.42 1.69 X 10-6
rs7611735 3 89186994 A 1164 0.2381 1.58 2.57 X 10-6
rs12095420 1 226788952 C 932 0.0098 7.03 2.58 X 10-6
rs75333138 2 38320106 C 1164 0.0903 0.50 2.75 X 10-6
rs13251066 8 59417753 A 1164 0.1637 1.65 3.10 X 10-6
DR= Diabetic retinopathy, RSID= rs identifier, CHR= chromosome, REF= reference allele, NEFF= Effective sample size, MAF = minor allele frequency, OR = 
odds ratio
Supplemental Table 23.  Ten independent variants with the lowest P values for the any DR Analysis, Europeans, Sensitivity Analysis, without accounting for 
covariates
RSID CHR POSITION REF* NEFF MAF OR P VALUE
rs4704979 5 155594567 T 1959 0.2229 1.46 3.22 X 10-6
rs1508244 6 87133646 A 1520 0.0248 0.33 3.74 X 10-6
rs150775408 3 82302346 C 1959 0.0527 2.03 4.59 X 10-6
rs200568615 10 128244089 AAAC/A 1713 0.2749 1.38 5.54 X 10-6
rs76512108 11 5613131 G 1831 0.2731 1.39 6.52 X 10-6
rs113264876 7 113173455 C 1959 0.0359 Undefined 6.66 X 10-6
rs3736388 3 124443522 T 1959 0.3967 1.31 8.23 X 10-6
rs4512907 12 97556471 G 1959 0.4074 0.75 8.23 X 10-6
rs1394919 4 76827946 C 1959 0.284 0.73 8.51 X 10-6
* For insertions/deletions, the first allele listed is the reference allele and the second allele listed is the non-reference allele. DR= Diabetic retinopathy, RSID= rs 
identifier, CHR= chromosome, REF= reference allele, NEFF= Effective sample size,  MAF = minor allele frequency, OR = odds ratio
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Supplemental Table 24.  Ten independent variants with the lowest P values for the sensitivity analysis excluding patients without DR from PDR 
Analysis (eg. NPDR vs PDR comparison), African Americans, with accounting for covariates
RESULTS FROM SENSITIVITY ANALYSIS: NPDR vs. PDR
RESULTS FROM MAIN PDR 
ANALYSIS FOR THESE SNPs
RSID CHR POSITION REF NEFF MAF OR P VALUE NEFF OR P VALUE
rs7548269 1 21089472 T 151 0.0932 3.22 5.36 X 10-8 1452 1.26 6.10 X 10-2
rs185674586 5 51231691 G 80 0.0124 Undefined 1.66 X 10-7 1220 0.93 5.40 X 10-1
rs12406144 1 21347228 A 151 0.0905 3.62 1.91 X 10-7 1452 1.24 3.26 X 10-2
rs62249672 3 77293697 C 109 0.0123 Undefined 2.72 X 10-7 1406 0.78 6.14 X 10-1
rs138903571 7 75079016 C 112 0.0167 Undefined 2.75 X 10-7 800 Undefined 2.92 X 10-3
rs144802783 10 13512079 G 109 0.0182 Undefined 3.15 X 10-7 1406 1.73 1.75 X 10-2
rs2374588 7 92441941 C 151 0.2096 2.20 3.50 X 10-7 1452 0.93 2.52 X 10-1
rs61781069 1 21130735 T 151 0.081 3.17 4.06 X 10-7 1452 1.20 1.63 X 10-1
rs6662707 1 21415321 G 151 0.0789 3.12 6.12 X 10-7 1452 1.27 6.81 X 10-2
rs139690049 7 92434043 A 151 0.1283 2.58 6.49 X 10-7 1452 0.93 4.11 X 10-1
DR= Diabetic retinopathy, PDR = Proliferative diabetic retinopathy, NPDR = Non-proliferative diabetic retinopathy, RSID= rs identifier, CHR= 
chromosome, REF= reference allele, NEFF= Effective sample size, MAF = minor allele frequency, OR = odds ratio
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Supplemental Table 25.  Ten independent variants with the lowest P values for the sensitivity analysis excluding patients without DR from PDR 
Analysis (eg. NPDR vs PDR comparison), Europeans, with accounting for covariates
RESULTS FROM SENSITIVITY ANALYSIS: NPDR vs. PDR
RESULTS FROM MAIN PDR 
ANALYSIS FOR THESE SNPs
RSID CHR POSITION REF NEFF MAF OR P VALUE NEFF OR P VALUE
rs828579 9 22166971 A 669 0.4268 1.52 2.17 X 10-8 1097 1.26 2.48 X 10-6
rs80004147 14 26897234 C 590 0.0205 Undefined 3.45 X 10-7 1018 Undefined 1.37 X 10-4
rs1087427 5 99705657 G 669 0.2396 1.80 6.96 X 10-7 1097 1.69 2.11 X 10-6
rs78271579 6 130313725 G 669 0.0802 0.45 1.13 X 10-6 1097 0.58 2.08 X 10-5
rs35174795 10 87399545 G 590 0.0441 0.22 1.61 X 10-6 1018 0.41 5.85 X 10-5
rs13187825 5 140677114 C 669 0.1963 0.61 3.75 X 10-6 1097 0.71 1.75 X 10-4
rs72742809 5 27832607 G 669 0.1997 1.72 3.84 X 10-6 1097 1.37 1.71 X 10-4
rs141100408 4 151508991 G 480 0.0201 0.27 4.26 X 10-6 907 0.88 1.47 X 10-2
rs142352402 10 109637245 G 480 0.0077 0.18 4.68 X 10-6 907 Undefined 1.19 X 10-5
rs77568641 6 68075850 A 480 0.0326 6.00 5.34 X 10-6 907 3.51 1.07 X 10-4
DR= Diabetic retinopathy, PDR = Proliferative diabetic retinopathy, NPDR = Non-proliferative diabetic retinopathy, RSID= rs identifier, CHR= 
chromosome, REF= reference allele, NEFF= Effective sample size, MAF = minor allele frequency, OR = odds ratio
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Supplemental Table 26.  Case/control sample sizes and allele frequencies per cohort for top DR associations.
Genotypes of QC-retained SNPs that did not survive filters in a given cohort were set to 'NA' in the given cohort. 
REF = reference allele, ALT = alternative allele, NCASE = number of cases, NCTRL =number of controls; FCASE = frequency of REF allele in cases, FCTRL = frequency of 
REF allele in controls, AAPDR= African American Proliferative Diabetic Retinopathy Study, AUST= Australian Genetics of Diabetic Retinopathy Study, FIND-Eye = Family 
Study of Nephropathy and Diabetes-Eye, JHS = Jackson Heart Study, MESA = Multiethnic Study of Atherosclerosis, WFU=Wake Forest University.
Analysis RSID CHR Position REF ALT Cohort NCASE NCTRL FCASE FCTRL
PDR AA EIG rs115523882 3 167876205 A G All 1105 1119 0.9823 0.9611
AAPDR 255 75 0.9804 0.92
FIND-Eye 279 246 0.9857 0.9695
JHS 12 239 1 0.9728
MESA 11 348 1 0.9698
WFU 548 211 0.9808 0.9384
PDR AA LTSOFT rs115523882 3 167876205 A G All 1105 1119 0.9823 0.9611
AAPDR 255 75 0.9804 0.92
FIND-Eye 279 246 0.9857 0.9695
JHS 12 239 1 0.9728
MESA 11 348 1 0.9698
WFU 548 211 0.9808 0.9384
PDR EU EIG rs139205645 2 201949806 T C All 309 975 0.9725 0.9959
AUST 187 770 0.9626 0.9955
FIND-Eye 122 205 0.9877 0.9976
PDR EU LTSOFT rs17791488 17 26232732 T G All 309 975 0.9871 0.9661
AUST 187 770 0.9813 0.9714
FIND-Eye 122 205 0.9959 0.9463
Extremes of DR 
AA EIG rs184340784 1 4589883 C T All 520 230 0.999 0.9784
AAPDR 255 56 0.998 0.9375
FIND-Eye 265 174 1 0.9915
Extremes of DR 
EU LT rs142293996 1 224448059 C A All 187 435 0.9947 0.9874
AUST 187 435 0.9947 0.9874
FIND-Eye NA NA NA NA
Extremes of DR 
EU LT rs17706958 3 73837141 T C All 308 594 0.8139 0.7332
AUST 187 435 0.8048 0.7322
FIND-Eye 121 159 0.8279 0.7358
Extremes of DR 
EU LT rs80117617 2 40855125 T G All 308 594 0.9838 0.9445
AUST 187 435 0.9786 0.9483
FIND-Eye 121 159 0.9918 0.934
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Supplemental Table 27. Replication results for variants with P < 5 x 10-8 (traditional, nominal threshold for genome wide significance) in the 
discovery analysis broken down by ethnicity 
Phenotype/ Discovery 
Population/
LT modeling
RSID REF AllNEFF
All 
RAF
All
OR
All
P
ASA
Rep
NEFF
ASA 
Rep
RAF
ASA
Rep 
OR
ASA
Rep 
P
HIS 
Rep 
NEFF
HIS 
Rep
RAF
HIS
Rep 
OR
HIS
Rep P
EUR 
NEFF
EUR
RAF
EUR
Rep 
OR
EUR
Rep 
P
PDR/AA/no rs115523882 A 571 0.9975 0.20 0.13 NA NA NA NA 571 0.9975 0.20 0.13 NA NA NA NA
PDR/AA/yes rs115523882 A 571 0.9975 0.20 0.18 NA NA NA NA 571 0.9975 0.20 0.18 NA NA NA NA
PDR/EUR/no rs139205645 T 3431 0.9900 0.74 0.77 NA NA NA NA 476 0.9962 0.99 0.59 2722 0.9889 0.72 0.87
PDR/EUR/yes rs17791488 T 5883 0.9772 0.82 0.33 NA NA NA NA 839 0.9769 1.26 0.61 4975 0.9772 0.76 0.20
Extremes of DR/AA/no rs184340784 C * * * * * * * * * * * * * * * *
Extremes of DR /EUR/yes rs142293996 C 1229 0.9910 3.23 0.16 NA NA NA NA 516 0.9951 6.29 0.36 654 0.9877 2.65 0.27
Extremes of DR /EUR/yes rs17706958 T 4194 0.9828 1.28 0.02 2322 0.9828 0.94 0.85 760 0.8802 1.69 0.0009 654 0.7787 1.13 0.51
Extremes of DR /EUR/yes rs80117617 T 3345 0.9726 1.29 0.24 NA NA NA NA 760 0.9860 1.58 0.31 2578 0.9687 1.24 0.39
LT= liability threshold, RSID= rs identifier, CHR= chromosome, REF= reference allele, NEFF= Effective sample size, RAF= reference allele 
frequency in sample, ALL= all replication cohorts, ASA Rep= Asian replication cohorts, HIS Rep= Hispanic replication cohorts, EUR Rep = 
European replication cohorts, OR= odds ratio for reference allele, AA= African American, EUR =  European, PDR = Proliferative diabetic 
retinopathy, DR = diabetic retinopathy, NA = not available
* None of the replication cohorts were able to provide data for this SNP.
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Supplemental Table 28. Testing robustness of top DR associations using Fisher's exact test on aggregated or separate cohorts.
RSID
Discovery 
analysis
Nearest 
Gene REF
gnomAD 
MAF§ Cohort NCase NCtrl FCase FCtrl
Fisher’s 
exact test 
P-value† OR 95% CI
Inverse 
variance-
weighted 
meta-
analysis P-
value†
Weighted 
average of 
effect sizes 
(OR)‡
rs115523882
PDR, AA, EIG 
or LTSCORE
GOLIM4 A 0.032 All 1105 1119 0.9823 0.9611 1.83X10-5 2.25 1.54-3.30 3.48X10-7 2.87
AAPDR 255 75 0.9804 0.92 9.71X10-4 4.35 1.84-10.28 - -
FIND-Eye 279 246 0.9857 0.9695 0.091 2.16 0.91-5.14 - -
JHS 12 239 1 0.9728 0.552 0.75 0.09-5.94 - -
MESA 11 348 1 0.9698 0.546 0.75 0.10-5.79 - -
WFU 548 211 0.9808 0.9384 8.32X10-5 3.36 1.87-6.04 - -
rs139205645
PDR, EUR, 
EIG
NDUFB3 T 0.015 All 309 975 0.9725 0.9959 3.73X10-6 0.15 0.06-0.34 1.72X10-6 0.13
AUST 187 770 0.9626 0.9955 2.89X10-6 0.12 0.05-0.29 - -
FIND-Eye 122 205 0.9877 0.9976 0.149 0.2 0.02-1.90 - -
rs17791488
PDR, EUR, 
LTSCORE
NOS2 / 
LYRM9
T 0.022 All 309 975 0.9871 0.9661 5.42X10-3 2.67 1.28-5.60 5.37X10-2 2.09
AUST 187 770 0.9813 0.9714 0.371 1.54 0.69-3.45 - -
FIND-Eye 122 205 0.9959 0.9463 3.21X10-4 13.78 1.85-102.9 - -
rs184340784
Extremes of 
DR, AA, EIG
AJAP1 C 0.003 All 520 230 0.999 0.9784 5.48X10-5 23.09 2.95-180.9 4.85X10-4 14.96
AAPDR 255 56 0.998 0.9375 3.57X10-5 33.93 4.13-278.7 - -
FIND-Eye 265 174 1 0.9915 0.084 6.14 0.68-55.15 - -
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RSID= rs identifier, AA= African Americans, EUR = European, CHR= chromosome, REF= reference allele, P_LTSOFT= P-value from meta-
analysis in Table 4, OR_LTSOFT= Odds ratio from meta-analysis in Table 4; NCASE= number of cases; NCTRL= number of controls; RAF= 
reference allele frequency, OR= odds ratio for reference allele, CI= confidence interval of OR, MAF= minor allele frequency. 
* The Fisher's exact test is two-tailed. 
†The weighted average of effect sizes across cohorts was computed using ln(OR) and variance of ln(OR). Variance of the ln(OR) was computed as 
1/(2x(NCASExRAF_CASE)) + 1/(2x(NCASEx(1-RAF_CASE))) + 1/(2x(NCTRLxRAF_CTRL)) 1/(2x(NCTRLx(1-RAF_CTRL))). 
‡OR were computed adding 1 to all four group counts, as one of the four group had 0 counts. This enabled to estimate an effect size for the meta-
analysis. The inverse variance-weighted meta-analysis P-values were computed using a chi-square cumulative distribution function assuming 1 
degree of freedom. P-values in bold pass Bonferroni correction (P<0.0036) correcting for 14 tests. The identity of the cohorts per variant can be 
found in Supplementary Table 27.
rs142293996
Extremes of 
DR, EUR, 
LTSCORE
NVL C 0.014 All 187 435 0.9947 0.9874 0.365 2.38 0.53-10.80 0.260 2.38
AUST 187 435 0.9947 0.9874 0.365 2.38 0.53-10.80 - -
rs17706958
Extremes of 
DR, EUR, 
LTSCORE
PDZRN3 T 0.209 All 308 594 0.8139 0.7332 1.52X10-4 1.59 1.25-2.02 2.34X10-4 1.57
AUST 187 435 0.8048 0.7322 6.36X10-3 1.51 1.12-2.03 - -
FIND-Eye 121 159 0.8279 0.7358 0.014 1.71 1.13-2.59 - -
rs80117617
Extremes of 
DR, EUR, 
LTSCORE
SLC8A1 T 0.043 All 308 594 0.9838 0.9445 3.45X10-5 3.56 1.82-6.98 6.43X10-4 3.24
AUST 187 435 0.9786 0.9483 0.014 2.5 1.16-5.35 - -
FIND-Eye 121 159 0.9918 0.934 3.88X10-4 8.48 1.97-36.55 - -
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Supplemental Table 29. Replication results for variants with nominal significance (P <0.05) in the replication cohorts broken down by ethnicity.
Discovery Population/
LT modeling RSID REF*
ALL 
OR
ALL 
P
ASA 
OR
ASA P EUR OR EUR P HIS OR HIS P
Variants identified in the Any DR Discovery Analysis
European (Sens)/no rs1394919 C 0.91 0.003 0.97 0.74 0.88 0.009 0.91 0.06
AA (Sens)/no rs75360147 T 2.65 0.009 NaN NaN NaN NaN 2.65 0.009
European/no rs1508244 A 0.92 0.01 0.95 0.14 0.74 0.02 0.83 0.07
ME/no rs10432638 C 0.93 0.01 0.98 0.93 0.92 0.05 0.89 0.05
EU/no rs150775408 C 1.27 0.04 2.57 0.17 1.21 0.15 1.19 0.30
AA/yes rs143894698 G 1.45 0.004 2.33 0.20 1.40 0.01 1.34 0.42
European/yes rs13006587 G 0.93 0.006 0.97 0.76 0.92 0.003 0.93 0.77
European/yes rs73642012 C 0.90 0.02 0.91 0.81 0.91 0.04 0.87 0.11
European/yes rs62295141 C 1.14 0.07 0.63 0.25 1.16 0.04 1.39 0.61
Variants identified in the PDR Discovery Analysis
Europeans/no rs139921826 G 0.66 0.03 NaN NaN 0.66 0.04 0.70 0.34
Europeans/no rs139618558 T 0.62 0.06 NaN NaN 0.58 0.04 2.44 0.34
AA/no rs1144964 G 0.99 0.61 0.85 0.01 1.05 0.48 1.12 0.29
AA/no rs137949823 G 1.02 0.92 0.81 0.03 1.06 0.45 1.22 0.17
AA/no rs7533141 T 1.00 0.57 1.35 0.04 0.94 0.55 1.13 0.23
European and ME/no rs202105116 C/CA 1.07 0.90 NaN NaN 1.11 0.71 0.37 0.006
AA/yes rs1414474 C 1.12 0.01 NaN NaN 1.11 0.06 1.23 0.07
AA/yes rs9998354 T 0.92 0.04 0.84 0.08 0.94 0.33 0.88 0.16
European/yes rs142293996 C 2.40 0.04 NaN NaN 2.24 0.06 5.09 0.42
AA/yes rs11612613 C 1.08 0.09 1.28 0.006 1.04 0.50 0.93 0.68
AA/yes rs202105116 C/CA 1.00 0.69 NaN NaN 1.14 0.57 0.37 0.006
Variants identified in the NPDR Discovery Analysis
European/no rs1508244 A 0.89 0.005 0.91 0.04 0.81 0.16 0.83 0.10
European/no rs7944308 G 0.94 0.02 0.94 0.07 0.97 0.55 0.88 0.06
European/no rs12199358 A 1.00 0.97 1.06 0.08 0.91 0.04 0.96 0.42
European/no rs1316491 T 1.00 0.89 1.03 0.29 1.02 0.725 0.86 0.02
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AA/no rs2104455 A 0.99 0.85 1.00 0.9049 0.94 0.15 1.17 0.03
AA/yes rs635762 C 0.97 0.78 0.73 0.02 1.05 0.53 0.99 0.72
AA/yes rs13089163 G 1.00 0.61 1.22 0.05 0.99 0.88 0.83 0.008
Variants identified in the Extremes of DR Discovery Analysis
AA/no rs74161190 A 0.40 0.03 NaN NaN #N/A #N/A 0.40 0.03
European/no rs202105116 C/CA 0.70 0.15 NaN NaN 1.42 0.4652 0.43 0.03
AA/no rs4129798 A 0.99 0.88 1.10 0.18 #N/A #N/A 0.79 0.03
European/yes rs17706958 T 1.28 0.02 0.94 0.85 1.13 0.51 1.69 0.0009
European/yes rs10932347 A 0.64 0.02 1.02 0.98 0.61 0.01 0.75 0.97
AA/yes rs2690028 C 0.80 0.03 1.06 0.52 0.70 0.03 0.92 0.41
European/yes rs116972715 C 3.62 0.03 NaN NaN 4.55 0.02 2.90 0.50
European/yes rs75167957 C 9.77 0.04 NaN NaN 16.94 0.01 0.53 0.65
AA/yes rs6577631 G 0.89 0.04 0.96 0.71 0.93 0.39 0.77 0.01
European/yes rs117752221 T 3.45 0.13 NaN NaN 6.58 0.04 0.81 0.72
European/yes rs114080992 G 1.00 0.24 0.86 0.25 0.71 0.36 1.69 0.0004
AA/yes rs17059444 C 1.14 0.15 1.84 0.42 1.12 0.57 1.40 0.03
* For insertions-deletion, the reference allele is shown first followed by the alternate allele
Sens= Sensitivity Analysis, ME = Multiethnic AA = African American, EUR = European, ASA = Asian, HIS = Hispanic
P-values of nominal significance (P <0.05) are bolded.
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Supplemental Table 30. Gene set enrichment analysis of 41 protein-protein interconnected genes.
Case Control 
Definition
Population # EXP genes/loci
above
95th percentile 
enrichment
cutoff
# OBS genes/loci
above
enrichment
cutoff
Excess #
genes/loci above
enrichment
cutoff
(OBS-EXP)†
Enrichment 
fold 
(OBS/EXP)
Nominal MAGENTA 
Enrichment P-value*
PDR  AA 2 33 31 16.5 <1x10-6
PDR EUR 2 1 0 0.5 0.871
Extremes of DR AA 2 8 6 4 2x10-4
Extremes of DR EUR 2 1 0 0.5 1
†Estimated number of genes that may be true associations with DR based on the MAGENTA analysis. None of the ‘most significant variant per gene’ 
for any of the 41 genes exceeded genome-wide significance (P<5x10-8). *To correct for physical clustering along the genome of subsets of genes 
within the gene set, genes that shared the same most significant variant were collapsed to one effective gene for the gene set enrichment analysis. AA 
= African American; EUR = European; OBS = observed; EXP = expected.
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Supplemental Table 31. MAGENTA gene association scores and most significant variants for 41 protein-protein interconnected genes based on 
African American PDR Discovery Analysis.
Gene Symbol Entrez ID
Gene 
association P-
value
Chr Gene Start Pos, hg19
Gene End 
Pos, hg19
Gene 
Size 
kb
# 
Variants 
per Gene 
Region
# LD 
Independent 
Variants per 
Gene Region
# 
Recombination 
Hotspots per 
Gene Region
Most 
Significant 
(Best) Variant 
per Gene 
Region
Best 
Variant Chr 
Pos hg19
Best Variant 
GWAS P-value
Best 
Variant 
log(OR)
Best 
Variant 
Allele 
Frequency 
gnomAD 
AFR
Best Variant 
Allele 
Frequency 
gnomAD 
EUR 
NonFinnish
DDX27 55661 1.06 X 10-05 20 47835831 47860614 25 703 22 0 rs2426139 47780105 2.60 X 10-06 -0.2643 0.4966 0.3035
COMMD1 150684 2.32 X 10-05 2 62132802 62363205 230 1464 53 3 rs7604016 62192135 1.41 X 10-06 -0.9255 0.9954 0.9946
CSE1L 1434 3.72 X 10-05 20 47662837 47713486 51 668 30 0 rs2426125 47700982 5.94 X 10-06 -0.2459 0.5207 0.3109
IMP3 55272 6.27 X 10-05 15 75931425 75932664 1 464 14 3 rs114597692 75936154 5.37 X 10-06 -1.23 0.03127 0.0001999
HIPK3 10114 9.52 X 10-05 11 33279167 33375939 97 720 45 3 rs12293762 33404732 6.74 X 10-06 0.6488 0.04415 0.0002009
ARFGEF2 10564 2.74 X 10-04 20 47538274 47653230 115 1100 36 2 rs201466610 47638974 7.69 X 10-06 -0.2413 NA NA
HSP90B1 7184 3.97 X 10-04 12 104324188 104341703 18 952 29 3 rs11612613 104260208 5.73 X 10-06 0.6967 0.05254 0.2606
SIN3A 25942 7.59 X 10-04 15 75661719 75748124 86 467 16 0 rs114768415 75803647 4.06 X 10-05 -1.0463 0.02832 0.0002668
POLR2E 5434 9.23 X 10-04 19 1086577 1095391 9 234 50 5 rs4147940 1066738 3.60 X 10-05 0.4863 0.06824 0.3329
TMEM62 80021 1.03 X 10-03 15 43425721 43477341 52 582 27 0 rs79649407 43315951 4.17 X 10-05 0.6893 0.02601 0.0004003
TCEB1 6921 1.52 X 10-03 8 74858633 74884346 26 912 29 3 rs79069049 74882703 1.55 X 10-05 0.8192 0.02876 0
ERP44 23071 2.37 X 10-03 9 102741462 102861330 120 744 30 0 rs138995597 102705139 5.54 X 10-05 -1.1597 0.01031 0
EIF2A 83939 2.77 X 10-03 3 150264573 150303803 39 771 26 2 rs73169821 150251045 3.85 X 10-05 -0.4267 0.1058 0.2003
CFH 3075 3.59 X 10-03 1 196621007 196716634 96 1205 37 2 rs16840419 196651745 2.98 X 10-05 -0.3582 0.2234 0.134
SELL 6402 4.35 X 10-03 1 169659805 169680843 21 1129 32 4 rs56747461 169654798 1.57 X 10-05 0.7781 0.05785 0.03848
UTP20 27340 4.43 X 10-03 12 101673904 101780397 106 1174 41 3 rs146262654 101665156 3.38 X 10-05 -1.6891 0.02431 0.0000672
PLAGL1 5325 4.47 X 10-03 6 144261436 144385735 124 1119 52 5 rs6570599 144319407 3.25 X 10-05 -0.3333 0.7662 0.6885
RBBP8 5932 5.03 X 10-03 18 20513294 20606449 93 1209 54 0 rs192950559 20548086 4.91 X 10-05 0.6514 0.02066 0
SEC61A2 55176 5.34 X 10-03 10 12171639 12211957 40 860 58 6 rs147716326 12235918 3.18 X 10-05 0.3912 0.08708 0.0002686
ALDH1B1 219 6.06 X 10-03 9 38392701 38398657 6 870 48 7 rs11791018 38406458 1.81 X 10-05 -0.5266 0.0466 0.1004
LIMS2 55679 6.24 X 10-03 2 128395995 128439360 43 985 31 2 rs13015157 128381594 4.61 X 10-05 0.4221 0.067 0.2018
CANX 821 6.76 X 10-03 5 179125929 179158639 33 960 50 3 rs13179916 179091092 4.42 X 10-05 -0.3249 0.1942 0.06963
HNRNPH1 3187 6.80 X 10-03 5 179041178 179050722 10 838 40 3 rs13179916 179091092 4.42 X 10-05 -0.3249 0.1942 0.06963
PPP2R2C 5522 7.11 X 10-03 4 6322304 6474326 152 1666 130 8 rs4247203 6351492 2.31 X 10-05 0.23 0.6022 0.7136
EEF1E1 9521 7.93 X 10-03 6 8073592 8102828 29 1050 41 4 rs60791514 8051387 3.28 X 10-05 0.308 0.2936 0.1851
CAP1 10487 9.21 X 10-03 1 40506254 40538321 32 888 32 3 rs6600316 40564905 5.80 X 10-05 0.478 0.07194 0.08137
NUP153 9972 9.69 X 10-03 6 17615268 17706818 92 1254 64 3 rs6925217 17588245 5.26 X 10-05 0.2452 0.4078 0.5126
PPT1 5538 9.74 X 10-03 1 40538381 40563142 25 948 28 2 rs6600316 40564905 5.80 X 10-05 0.478 0.07194 0.08137
SPON1 10418 1.08 X 10-02 11 13983913 14289655 306 2329 72 7 rs140991985 13952047 2.29 X 10-05 1.2544 0.01271 0
IFNG 3458 1.11 X 10-02 12 68548549 68553521 5 997 45 3 rs2193044 68534441 4.26 X 10-05 -0.5161 0.9376 0.7288
MYO1E 4643 1.36 X 10-02 15 59428562 59665071 237 2316 115 10 rs17269587 59592116 2.10 X 10-05 0.3447 0.2642 0.315
ARHGAP15 55843 1.36 X 10-02 2 143886898 144525921 639 2996 130 9 rs41429953 144089893 1.47 X 10-05 1.0488 0.01834 0.00006672
TAF4 6874 1.39 X 10-02 20 60549853 60640866 91 1421 52 2 rs6061931 60543295 5.78 X 10-05 0.7307 0.08257 0.002335
ADAMTS9 56999 1.50 X 10-02 3 64501330 64673365 172 1852 87 8 rs4401354 64649949 3.17 X 10-05 0.2934 0.5194 0.6391
IL22RA1 58985 1.98 X 10-02 1 24446260 24469611 23 915 43 7 rs34654982 24496085 5.02 X 10-05 -0.2501 0.2635 0.03499
CAP2 10486 2.41 X 10-02 6 17393735 17558023 164 1734 64 7 rs6925217 17588245 5.26 X 10-05 0.2452 0.4078 0.5126
THRB 7068 4.63 X 10-02 3 24158644 24536313 378 2915 129 10 rs73823307 24520940 4.95 X 10-05 0.9898 0.02485 0.0002002
NUP50 10762 6.27 X 10-02 22 45559725 45583890 24 1050 68 7 rs115404138 45566422 1.17 X 10-04 0.925 0.02303 0
SEC61B 10952 8.65 X 10-02 9 101984569 101992901 8 401 28 3 rs77676592 102032626 7.43 X 10-04 0.7095 0.01225 0.00006668
WFS1 7466 3.40 X 10-01 4 6271576 6304992 33 756 90 4 rs6849178 6235405 2.24 X 10-03 -0.2338 0.3538 0.3047
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ATM 472 9.48 X 10-01 11 108093558 108239826 146 1292 42 0 rs181987872 108036580 2.99 X 10-02 -0.5971 0.018 0.000271
Gene association p-values were computed based on the GWAS p-value of the most significant variant per gene region (+110kb/-40kb) from the 
African American PDR Discovery Analysis GWAS, correcting for gene size, number of variants per gene region, number of ancestry-specific, LD 
independent variants per gene region, and number of recombination hotspots spanning the gene region, using step-wise multivariate linear regression 
analysis. Pos, position; LD, linkage disequilibrium; OR, odds ratio; AFR, African American; EUR, European; Chr, chromosome.
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Supplemental Table 32.  Correlation between type 2 diabetes and glycemic trait variants and any diabetic retinopathy case status.
Trait R Z score P value
Type 2 diabetes +0.0458 +2.256 0.024
Fasting glucose +0.0099 +0.490 0.624
Fasting insulin +0.0130 +0.638 0.523
HbA1c -0.0109 -0.539 0.590
Pro-insulin +0.0213 +1.051 0.293
2-hour glucose +0.0228 +1.122 0.266
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Supplemental Table 33.  Results for SNPs previously associated with diabetic retinopathy in other genetic studies of diabetic retinopathy.
Present study P 
value
AA
Study Cases #(Definition)
Controls 
#(Definition)
 
Diabetes 
Type
Covariates 
adjusted for Ethnicity Top SNPs
Nearest 
Gene
Risk 
allele
Original 
study 
OR
Original 
Study 
P value 
Present study 
case-control 
definition
Present 
study P 
value 
European 
rs6909083 TINAG NA NA 2 x 10-5
Any DR 
(with 
covariates)
0.558 0.508
rs17083119 TBC1D32 NA NA 3 X 10-5 Any DR NA 0.562
Fu et al 
2010*
103 (moderate to 
severe NPDR 
and PDR)
183 (no 
retinopathy to 
early NPDR)
2
Age, sex, 
diabetes duration 
and HbA1c
Mexican 
American
rs2300782 CAMK4 A 2.64 6 X10-5 Any DR 0.429 0.227
rs17376456 KIAA0825 A 3.63 3 x 10-15 Any DR 0.776 0.141
rs2038823 HS6ST3 C 2.33 5 x 10-11 Any DR 0.255 0.801
rs4838605 ARHGAP22 C 1.58 2 x 10-9 Any DR 0.898 0.47
rs12219125 PLXDC2 T 1.62 9 X 10-9 Any DR 0.476 0.471
Huang et 
al 2011
174 (NPDR and 
PDR)
575 diabetic 
patients without 
DR and 100 
nondiabetic 
patients
2
Diabetes 
duration and 
HbA1c
Chinese
rs4462262 MIR3924 C 1.54 <9 X 10-8 Any DR 0.567 0.104
rs476141 LOC339529 A 1.37 1 X 10-7 PDR 0.927 0.067
rs4787008 RBFOX1 G 1.47 6 x 10-7 PDR 0.63 0.124Grassi et al 2011
973 (PDR and 
DME)
1856 (all others, 
including NPDR) 1 None European
rs13064954 CCNL1 G 1.02 7 X 10-7 PDR 0.388 0.525
rs9565164 TBC1D4 C 1.7 1 x 10-7 Extremes of DR NA NA
rs1399634 LRP2 A 1.5 2 x 10-6 Extremes of DR 0.0124 0.781
Sheu et al 
2013† 437 (PDR)
570 (no DR with 
diabetes for at least 
8 years)
2 None Chinese
rs2380261 AF279775 T 1.5 2 x 10-6 Extremes of DR 0.951 0.867
Awata et 
al 2014‡ 837 (any DR) 1149 (no DR) 2
Sex, duration of 
diabetes and 
HbA1c
Japanese rs9362054 LINC01611 T 1.64 1.4 x 10-7 Any DR 0.668 0.329
Burdon et 
al 2016
336 (sight-
threatening 
DR)
508 (no or minimal 
DR) 2
Age, sex, 
duration of 
diabetes, HbA1c, 
blood pressure, 
kidney disease
European rs9896052 GRB2 A 1.67 4.7 X 10-8 Extremes of DR 0.006 0.15
Luo et al 
2013 383 (PDR) 756 (no DR) 2 BMI European rs7903146 TCF7L2 T 1.37 1.1 x 10
-3 Extremes of 
DR 0.815 0.971
Tong et al 
2008 1618 (PDR) 954 (no DR) 1 and 2 None European rs1617640 EPO T 1.3 5.5 x10
-11 Extremes of 
DR 0.364 0.743
rs6128 SELP T 0.43 0.0001 Any DR 0.0119 0. 367Sobrin et 
al 2011
222 
(ETDRS>=14 or 
ETDRS >=30)
1032 (no DR) 2 None European
rs6856425 SLC26A1 C 3.83 0.0001 Any DR 0.371 NA
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DR = diabetic retinopathy; PDR = proliferative diabetic retinopathy; NPDR = non-proliferative diabetic retinopathy; ETDRS = Early Treatment Diabetic Retinopathy Study Score; 
BMI = body mass index; DME = diabetic macular edema; HbA1c = hemoglobin A1c; NA = not available
* Samples from this study overlap partially with the samples from the Starr County Health Studies samples which provided replication data as part of the current study.
† Samples from this study overlap partially with the samples from the Taiwan-US Diabetic Retinopathy study which provided replication data as part of the current study.
‡ Samples from this study overlap partially with the samples from the Rikagaku Kenkyusho - Institute of Physical and Chemical Research (RIKEN) study which provided 
replication data as part of the current study.
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Supplemental Table 34.  List of Type 2 Diabetes and Associated Glycemic Traits Variants 
SNPs divided by glycemic traits
2 hour glucose Type 2 Diabetes Fasting Glucose HbA1c Fasting Insulin* Pro-Insulin
rs11782386 rs10923931 rs2943640 rs2447090 rs9368222 rs10830963 rs2191349 rs17533903 rs4841132 rs7903146
rs1260326 rs2075423 rs10203174 rs11651052 rs10811661 rs13179048 rs4607517 rs17747324 rs780094 rs11558471
rs6975024 rs17106184 rs243088 rs12970134 rs6048205 rs3783347 rs10830963 rs198846 rs17036328 rs11603334
rs11672660 rs11257655 rs4812829 rs10401969 rs1371614 rs16913693 rs11708067 rs2110073 rs141203811 rs4790333
rs1436958 rs12242953 rs2023681 rs8182584 rs780094 rs10885122 rs2779116 rs2375278 rs731839 rs10501320
rs1019503 rs12571751 rs1801282 rs8108269 rs2293941 rs7903146 rs552976 rs2383208 rs4646949 rs10838687
rs12255372 rs1111875 rs4402960 rs7569522 rs576674 rs3802177 rs1800562 rs2408955 rs4865796 rs4502156
rs11717195 rs2334499 rs17301514 rs13389219 rs10305492 rs11708067 rs1799884 rs267738 rs1421085 rs1549318
rs7651090 rs5215 rs6808574 rs1552224 rs6072275 rs10747083 rs16926246 rs282587 rs459193 rs6235
rs231360 rs1496653 rs10830963 rs4607517 rs651007 rs1387153 rs3782123 rs1167800
rs163184 rs12497268 rs7903146 rs11605924 rs3829109 rs7998202 rs3824065 rs3822072
rs1061810 rs6795735 rs3802177 rs2302593 rs1046896 rs4737009 rs35767
rs12427353 rs6819243 rs459193 rs7944584 rs855791 rs4783565 rs974801
rs4275659 rs6813195 rs1483121 rs10774625 rs4820268 rs2745353
rs10842994 rs4458523 rs11715915 rs11154792 rs579459 rs1530559
rs11063069 rs702634 rs6943153 rs11224302 rs592423 rs4691380
rs2261181 rs6878122 rs2657879 rs11248914 rs6474359 rs10195252
rs7955901 rs11759026 rs174550 rs11558471 rs6980507 rs7607980
rs1359790 rs3130501 rs11071657 rs11603334 rs7040409 rs2785980
rs7177055 rs4299828 rs1552224 rs11619319 rs7616006 rs2943634
rs11634397 rs3734621 rs7708285 rs11964178 rs7756992
rs2007084 rs9505118 rs10830963 rs12621844 rs8192675
rs12899811 rs17867832 rs13179048 rs13134327 rs837763
rs9936385 rs11717195 rs3783347 rs1467311 rs857691
rs7202877 rs10811661 rs560887 rs1558902 rs9604573
rs2925979 rs7756992 rs11920090 rs174577 rs9818758
rs780094 rs4502156 rs340874 rs17509001 rs9914988
*adjusted for body mass index
HbA1c = hemoglobin A1c
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Supplemental Figures
Supplemental Figure 1. Summary of analysis performed. Green boxes represent final analyses and results can be found in main tables and 
Supplemental tables.
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Supplemental Figure 2. Principal components analysis results for cohorts included in the primary (any DR) discovery meta-analysis
A. African Americans
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B. Europeans
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Supplemental Figure 3.  Quantile-quantile plots of the results for the primary (any DR) discovery meta-analyses for (A) African American 
participants without accounting for duration of diabetes and glycemic control (EIGENSOFT analysis), (B) African American participants with 
liability threshold modeling of duration of diabetes and glycemic control (LTSCORE analysis), (C) European participants without accounting for 
duration of diabetes and glycemic control (EIGENSOFT analysis) and (D) European participants with liability threshold modeling of duration of 
diabetes and glycemic control (LTSCORE analysis). The λgc value was 1.0009 for both the EIGENSOFT and LTSCORE association analyses for 
African Americans. The λgc values were 1.0059 and 0.9912 for the EIGENSOFT and LTSCORE association analyses, respectively, for Europeans.  
A. African American participants without accounting for duration 
of diabetes and glycemic control
B. African American participants with liability threshold modeling 
of duration of diabetes and glycemic control
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C. European participants without accounting for duration of 
diabetes and glycemic control
D. European participants with liability threshold modeling of 
duration of diabetes and glycemic control
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Supplemental Figure 4.  Manhattan plots for the primary (any DR) discovery meta-analyses for (A) African American participants without 
accounting for duration of diabetes and glycemic control, (B) African American participants with liability threshold modeling of duration of diabetes 
and glycemic control, (C) European participants without accounting for duration of diabetes and glycemic control and (D) European participants with 
liability threshold modeling of duration of diabetes and glycemic control.
A. African American participants without accounting for 
duration of diabetes and glycemic control
B. African American participants with liability threshold 
modeling of duration of diabetes and glycemic control
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C.   European participants without accounting for duration of 
diabetes and glycemic control
D. European participants with liability threshold modeling of 
duration of diabetes and glycemic control
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Supplemental Figure 7. Distribution of proliferative diabetic retinopathy (PDR) gene association P values for DAPPLE significant genes in African 
Americans (AA) and Europeans. A noncumulative distribution of gene association P values, computed with MAGENTA, is shown for 41 genes in 
top ranked AA PDR Analysis GWAS loci, enriched for protein-protein interactions based on the DAPPLE analysis. The enrichment of top ranked 
gene P values using the AA PDR GWAS (line with arrow) is contrasted against the more uniform distribution of gene P values computed with the 
European (EUR) PDR GWAS (line with boxes). A bin of 0.1 was used. The dashed line marks the 95th percentile enrichment cutoff used by 
MAGENTA in the AA PDR analysis. The vertical lines in the bottom two tracks correspond to the individual gene P values based on AA or EUR 
PDR GWAS.
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